[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$figRZcWy75H57GapahG8eeqyT6I4W0ruckWBo5VMY0Gc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":86,"rows":93},"London School of Hygiene and Tropical Medicine",[4],296,false,18,86,4749932,14,158,[14,17,20,23,26,29,31,33],{"name":15,"count":16},"Malaria",93,{"name":18,"count":19},"Anaemia",12,{"name":21,"count":22},"Diarrhea",10,{"name":24,"count":25},"Anemia",9,{"name":27,"count":28},"HIV Infections",8,{"name":30,"count":28},"Pregnancy",{"name":32,"count":28},"Malaria,Falciparum",{"name":34,"count":35},"Myocardial Infarction",7,[37,42,47,52,57,62,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT02834637","A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls","2020-01-15","bivalent HPV vaccine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06578572","Seasonal R21 Mass Vaccination for Malaria Elimination","2024-12-31","R21Matrix M",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04945681","Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People","2025-01-18","Pneumococcal conjugate vaccine",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05856357","Perennial Malaria Chemoprevention (PMC) in Côte D'Ivoire","2025-06","Sulfadoxine pyrimethamine",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05562609","Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women At Higher Risk","2025-08","Tranexamic acid",{"nctId":63,"briefTitle":64,"date":65,"intervention":56},"NCT05889052","Perennial Malaria Chemoprevention (PMC) in Cameroon","2025-09",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03775460","Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum","2025-09-01","Methotrexate",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT04953130","Adding Male Single Dose HPV Vaccination to Female HPV Vaccination in Tanzania","2025-11","Gardasil® HPV vaccine",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04521881","Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults","2026-12-31","Tranexamic Acid 500 MG",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT06921213","Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis","2027-03-31","Linezolid",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,132,154,187,263,286,304,325,353,391,409,427,473,523,541,616,687,744,805,840,869,887,905,923,951,969,987,1005,1030,1048,1077,1095,1113,1141,1159,1177,1195,1221,1246,1271,1289,1307,1325,1343,1366,1392,1451,1485,1528,1577,1615,1650,1681,1720,1742,1764,1793,1828,1850,1876,1894,1922,1940,1958,1976,1994,2017,2043,2068,2090,2112,2138,2156,2174,2192,2210,2228,2255,2273,2291,2309,2339,2357,2375,2400,2424,2447,2472,2495,2519,2537,2555,2573,2598,2616,2634,2652,2678,2696,2714,2732,2756,2774,2792,2810,2828,2846,2864,2888,2911,2929,2947,2971,2989,3013,3031,3054,3079,3097,3120,3145,3163,3181,3199,3224,3242,3260,3282,3300,3327,3345,3363,3381,3399,3417,3439,3457,3475,3493,3529,3556,3574,3592,3617,3641,3667,3692,3710,3728,3750,3768,3786,3804,3822,3849,3867,3885,3909,3927,4005,4065,4117,4155,4185,4227,4253,4275,4293,4322,4346,4369,4393,4418,4436,4454,4477,4501,4519,4542,4568],{"intervention":75,"totalTrials":95,"cells":96},2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":130},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":129,"soonestReadout":74},[108,119],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":118},"NCT01173900","Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls","COMPLETED",[91],"2011-08","2010-08",5532,[117],"Cervical Cancer",[75],{"nctId":72,"briefTitle":73,"status":120,"phases":121,"primaryCompletion":74,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":128},"ACTIVE_NOT_RECRUITING",[91],"2026-10","2022-08-01",10400,[126,127],"HPV Infection","Vaccine Preventable Disease",[75],1,{"trials":131,"activeCount":99},[],{"intervention":51,"totalTrials":129,"cells":133},{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":152},{"trials":135,"activeCount":99},[],{"trials":137,"activeCount":99},[],{"trials":139,"activeCount":99},[],{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":129,"soonestReadout":50},[144],{"nctId":48,"briefTitle":49,"status":120,"phases":145,"primaryCompletion":50,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},[91],"2026-02-28","2022-11-27",2882,[150],"Pneumococcal Infections",[51],{"trials":153,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":183,"NA":185},{"trials":157,"activeCount":99},[],{"trials":159,"activeCount":99},[],{"trials":161,"activeCount":99},[],{"trials":163,"activeCount":95,"soonestReadout":79},[164,173],{"nctId":77,"briefTitle":78,"status":165,"phases":166,"primaryCompletion":79,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"RECRUITING",[90],"2028-01-31","2021-04-18",5000,[171],"Traumatic Brain Injury",[80],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"completion":179,"start":65,"enrollment":180,"conditions":181,"interventions":182},"NCT06519422","Tranexamic Acid for Anaemia Trial","NOT_YET_RECRUITING",[90],"2028-08","2028-09",4000,[24],[80],{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":99},[],{"intervention":188,"totalTrials":189,"cells":190},"Tranexamic Acid",6,{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":197,"PHASE4":259,"NA":261},{"trials":192,"activeCount":99},[],{"trials":194,"activeCount":99},[],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":129,"soonestReadout":60},[199,209,218,230,237,248],{"nctId":200,"briefTitle":201,"status":111,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":208},"NCT01658124","Haemorrhage Alleviation With Tranexamic Acid- Intestinal System",[90],"2019-07-19","2013-07",12009,[207],"Gastrointestinal Bleeding",[188],{"nctId":210,"briefTitle":211,"status":111,"phases":212,"primaryCompletion":213,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":217},"NCT01402882","Clinical Randomisation of an Antifibrinolytic in Significant Head Injury",[90],"2019-10","2012-07",12737,[171],[188],{"nctId":219,"briefTitle":220,"status":111,"phases":221,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":226,"interventions":228},"NCT00375258","Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage",[90],"2010-02","2010-03","2005-05",20211,[227],"Hemorrhage",[61,229],"Sodium Chloride 0.9%",{"nctId":58,"briefTitle":59,"status":165,"phases":231,"primaryCompletion":60,"completion":65,"start":232,"enrollment":233,"conditions":234,"interventions":236},[90],"2024-04-22",30000,[235],"Postpartum Hemorrhage",[61],{"nctId":238,"briefTitle":239,"status":111,"phases":240,"primaryCompletion":241,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT03475342","World Maternal Antifibrinolytic Trial_2",[90],"2023-09-20","2023-10-29","2019-08-24",15068,[246],"Intrapartum - Moderate and Severe Anaemia",[188],{"nctId":249,"briefTitle":250,"status":111,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":258},"NCT00872469","World Maternal Antifibrinolytic Trial",[90],"2016-06","2017-04","2009-05",20060,[257],"Postpartum Haemorrhage",[61],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":99},[],{"intervention":41,"totalTrials":129,"cells":264},{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":269,"PHASE3":271,"PHASE4":282,"NA":284},{"trials":266,"activeCount":99},[],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":129,"soonestReadout":40},[273],{"nctId":38,"briefTitle":39,"status":120,"phases":274,"primaryCompletion":40,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},[90],"2027-03","2017-02-23",930,[279],"Human Papilloma Virus",[41,281],"nonavalent HPV vaccine",{"trials":283,"activeCount":99},[],{"trials":285,"activeCount":99},[],{"intervention":281,"totalTrials":129,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":294,"PHASE4":300,"NA":302},{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":129,"soonestReadout":40},[296],{"nctId":38,"briefTitle":39,"status":120,"phases":297,"primaryCompletion":40,"completion":275,"start":276,"enrollment":277,"conditions":298,"interventions":299},[90],[279],[41,281],{"trials":301,"activeCount":99},[],{"trials":303,"activeCount":99},[],{"intervention":46,"totalTrials":129,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":312,"PHASE4":321,"NA":323},{"trials":307,"activeCount":99},[],{"trials":309,"activeCount":99},[],{"trials":311,"activeCount":99},[],{"trials":313,"activeCount":129,"soonestReadout":45},[314],{"nctId":43,"briefTitle":44,"status":165,"phases":315,"primaryCompletion":45,"completion":316,"start":317,"enrollment":318,"conditions":319,"interventions":320},[90],"2025-12-31","2024-05-30",16200,[15],[46],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"intervention":326,"totalTrials":129,"cells":327},"PvSeroTAT",{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":349,"NA":351},{"trials":329,"activeCount":99},[],{"trials":331,"activeCount":99},[],{"trials":333,"activeCount":99},[],{"trials":335,"activeCount":129,"soonestReadout":340},[336],{"nctId":337,"briefTitle":338,"status":165,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":348},"NCT06923592","Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar",[90],"2027-04-28","2025-05-12",19200,[344,345,346,347],"Malaria Vivax","Malaria Falciparum","Plasmodium Vivax","Plasmodium Falciparum",[326],{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":99},[],{"intervention":354,"totalTrials":95,"cells":355},"Amoxicillin",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":371,"PHASE4":387,"NA":389},{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":129,"soonestReadout":84},[362],{"nctId":82,"briefTitle":83,"status":165,"phases":363,"primaryCompletion":84,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},[89],"2027-06-30","2026-05-04",90,[368],"Syphilis, Congenital",[85,354,370],"Benzathine Penicillin G",{"trials":372,"activeCount":99},[373],{"nctId":374,"briefTitle":375,"status":111,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":385},"NCT03545373","Accuracy and Consequences of Using Trial-of-antibiotics for TB Diagnosis (ACT-TB Study)",[90],"2020-03-14","2020-04-14","2019-02-25",1583,[382,383,384],"Tuberculosis","Respiratory Tract Infections","Pneumonia",[386,354],"Azithromycin",{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":85,"totalTrials":129,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":129,"soonestReadout":84},[399],{"nctId":82,"briefTitle":83,"status":165,"phases":400,"primaryCompletion":84,"completion":364,"start":365,"enrollment":366,"conditions":401,"interventions":402},[89],[368],[85,354,370],{"trials":404,"activeCount":99},[],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"intervention":370,"totalTrials":129,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":421,"PHASE4":423,"NA":425},{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":129,"soonestReadout":84},[417],{"nctId":82,"briefTitle":83,"status":165,"phases":418,"primaryCompletion":84,"completion":364,"start":365,"enrollment":366,"conditions":419,"interventions":420},[89],[368],[85,354,370],{"trials":422,"activeCount":99},[],{"trials":424,"activeCount":99},[],{"trials":426,"activeCount":99},[],{"intervention":56,"totalTrials":428,"cells":429},3,{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":99},[],{"trials":437,"activeCount":99},[],{"trials":439,"activeCount":99},[],{"trials":441,"activeCount":95,"soonestReadout":55},[442,448,454],{"nctId":53,"briefTitle":54,"status":120,"phases":443,"primaryCompletion":55,"completion":65,"start":444,"enrollment":445,"conditions":446,"interventions":447},[],"2023-08-11",1568,[15,24],[56],{"nctId":63,"briefTitle":64,"status":120,"phases":449,"primaryCompletion":65,"completion":65,"start":450,"enrollment":451,"conditions":452,"interventions":453},[],"2023-07-19",2080,[24,15],[56],{"nctId":455,"briefTitle":456,"status":457,"phases":458,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":463,"interventions":469},"NCT05354258","Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children","UNKNOWN",[92],"2022-11-30","2023-09","2022-06-16",600,[15,464,465,466,467,468],"Soil Transmitted Helminths","Schistosomiasis","Integrated Control","Seasonal Malaria Chemoprevention","Mass Drug Administration With Anthelminthic Drugs",[470,471,472,56],"Albendazole","Praziquantel","Amodiaquine",{"intervention":474,"totalTrials":475,"cells":476},"prednisolone",4,{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":501,"PHASE4":511,"NA":513},{"trials":478,"activeCount":99},[],{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":99},[483,493],{"nctId":484,"briefTitle":485,"status":111,"phases":486,"primaryCompletion":487,"completion":204,"start":114,"enrollment":488,"conditions":489,"interventions":491},"NCT00919776","Ciclosporin in the Management of Chronic or Recurrent Erythema Nodosum Leprosum",[89],"2012-12",20,[490],"Leprosy",[474,492],"ciclosporin",{"nctId":494,"briefTitle":495,"status":111,"phases":496,"primaryCompletion":487,"completion":204,"start":497,"enrollment":19,"conditions":498,"interventions":499},"NCT00919542","Ciclosporin in the Management of New Erythema Nodosum Leprosum",[89],"2010-07",[490],[500,474],"Ciclosporin",{"trials":502,"activeCount":99},[503],{"nctId":504,"briefTitle":505,"status":111,"phases":506,"primaryCompletion":487,"completion":204,"start":114,"enrollment":507,"conditions":508,"interventions":509},"NCT00919815","Ciclosporin in the Management of New Type 1 Reactions in Leprosy",[89,90],73,[490],[500,510],"Prednisolone",{"trials":512,"activeCount":99},[],{"trials":514,"activeCount":129,"soonestReadout":69},[515],{"nctId":67,"briefTitle":68,"status":120,"phases":516,"primaryCompletion":69,"completion":517,"start":518,"enrollment":519,"conditions":520,"interventions":522},[92],"2025-10-01","2023-01-15",550,[521],"Erythema Nodosum Leprosum",[70,510],{"intervention":70,"totalTrials":129,"cells":524},{"EARLY_PHASE1":525,"PHASE1":527,"PHASE2":529,"PHASE3":531,"PHASE4":533,"NA":535},{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":99},[],{"trials":530,"activeCount":99},[],{"trials":532,"activeCount":99},[],{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":129,"soonestReadout":69},[537],{"nctId":67,"briefTitle":68,"status":120,"phases":538,"primaryCompletion":69,"completion":517,"start":518,"enrollment":519,"conditions":539,"interventions":540},[92],[521],[70,510],{"intervention":386,"totalTrials":189,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":586,"NA":614},{"trials":544,"activeCount":99},[],{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":99},[551,562,566,576],{"nctId":552,"briefTitle":553,"status":111,"phases":554,"primaryCompletion":555,"completion":556,"start":252,"enrollment":557,"conditions":558,"interventions":561},"NCT02426112","Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children",[90],"2018-09","2019-08",347,[559,560],"Chronic Lung Disease","HIV Infection",[386],{"nctId":374,"briefTitle":375,"status":111,"phases":563,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":564,"interventions":565},[90],[382,383,384],[386,354],{"nctId":567,"briefTitle":568,"status":111,"phases":569,"primaryCompletion":570,"completion":570,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT02344628","Comparison of Two Different Doses of Azithromycin for Treatment of Yaws",[90],"2016-12","2015-06",583,[574],"Yaws",[386],{"nctId":577,"briefTitle":578,"status":111,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT03199547","Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death",[90],"2021-05-31","2017-10-21",11985,[584],"Neonatal SEPSIS",[386],{"trials":587,"activeCount":99},[588,602],{"nctId":589,"briefTitle":590,"status":111,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":599},"NCT02775617","Azithromycin - Ivermectin Mass Drug Administration for Skin Disease",[91],"2017-08","2018-02-05","2016-07",1291,[597,574,598],"Scabies","Impetigo",[600,386,601],"Ivermectin","Permethrin",{"nctId":603,"briefTitle":604,"status":111,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":612},"NCT02972957","A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia",[91],"2018-12-19","2019-05-23","2017-01-30",364,[611],"Influenza",[613,386],"Nasovac-S",{"trials":615,"activeCount":99},[],{"intervention":600,"totalTrials":617,"cells":618},5,{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":623,"PHASE3":625,"PHASE4":679,"NA":685},{"trials":620,"activeCount":99},[],{"trials":622,"activeCount":99},[],{"trials":624,"activeCount":99},[],{"trials":626,"activeCount":99},[627,639,654,667],{"nctId":628,"briefTitle":629,"status":111,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":636},"NCT03576313","Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Malaria Elimination",[90],"2019-12-31","2021-07-31","2018-08-11",4939,[15],[637,638],"dihydroartemisinin-piperaquine","ivermectin",{"nctId":640,"briefTitle":641,"status":457,"phases":642,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":647,"interventions":652},"NCT04844905","Adjunctive Ivermectin Mass Drug Administration for Malaria Control",[90],"2023-03","2023-08","2021-05-03",24000,[32,648,649,650,597,651,464],"Neglected Tropical Diseases","Strongyloidiasis","Lymphatic Filariasis","Hook Worm",[600,653],"Dihydroartemisinin-piperaquine",{"nctId":655,"briefTitle":656,"status":111,"phases":657,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":662,"interventions":664},"NCT03236168","Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands",[90],"2017-12-31","2018-02-28","2017-08-01",118,[597,663],"Head Lice",[600,665,666],"Permethrin 5%","Malathion Shampoo 0.5%",{"nctId":668,"briefTitle":669,"status":457,"phases":670,"primaryCompletion":671,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":677},"NCT04703608","Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia",[90],"2022-03","2022-07","2021-01-22",1200,[676],"Covid-19",[600,678],"ASP",{"trials":680,"activeCount":99},[681],{"nctId":589,"briefTitle":590,"status":111,"phases":682,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":683,"interventions":684},[91],[597,574,598],[600,386,601],{"trials":686,"activeCount":99},[],{"intervention":688,"totalTrials":475,"cells":689},"Sulfadoxine-pyrimethamine plus amodiaquine",{"EARLY_PHASE1":690,"PHASE1":692,"PHASE2":694,"PHASE3":718,"PHASE4":731,"NA":742},{"trials":691,"activeCount":99},[],{"trials":693,"activeCount":99},[],{"trials":695,"activeCount":99},[696,708],{"nctId":697,"briefTitle":698,"status":111,"phases":699,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":703,"interventions":705},"NCT01319448","Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease",[88,89],"2013-04","2011-09",270,[15,704],"Sickle Cell Crisis",[706,707,688],"Proguanil","mefloquine plus artesunate",{"nctId":709,"briefTitle":710,"status":111,"phases":711,"primaryCompletion":712,"completion":712,"start":713,"enrollment":714,"conditions":715,"interventions":716},"NCT01328990","Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine for Intermittent Preventive Treatment in Children (IPTc)",[88,89],"2011-07","2011-04",150,[15],[717],"sulfadoxine-pyrimethamine plus amodiaquine",{"trials":719,"activeCount":99},[720],{"nctId":721,"briefTitle":722,"status":111,"phases":723,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT00118807","Trial of the Effectiveness of AQ\u002FAS, SP\u002FAQ and SP\u002FCQ for Uncomplicated Malaria in Gambian Children",[90],"2004-02","2003-08",1800,[15],[729,730,688],"Amodiaquine plus artesunate","Sulfadoxine-pyrimethamine plus chloroquine",{"trials":732,"activeCount":99},[733],{"nctId":734,"briefTitle":735,"status":457,"phases":736,"primaryCompletion":737,"completion":214,"start":738,"enrollment":739,"conditions":740,"interventions":741},"NCT00712374","Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal",[91],"2011-12","2008-09",100000,[15],[717],{"trials":743,"activeCount":99},[],{"intervention":745,"totalTrials":475,"cells":746},"Artemether-lumefantrine",{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":751,"PHASE3":777,"PHASE4":791,"NA":803},{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[753,765],{"nctId":754,"briefTitle":755,"status":111,"phases":756,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":761,"interventions":762},"NCT05550909","Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali",[89],"2022-12-30","2023-01-26","2022-10-17",100,[32],[763,764,745,472],"Artesunate-amodiaquine combination","Primaquine Phosphate",{"nctId":766,"briefTitle":767,"status":111,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":774},"NCT05081089","Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali",[89],"2021-12-16","2022-01-13","2021-10-12",80,[32],[745,764,775,776],"Sulphadoxine-pyrimethamine with amodiaquine","Tafenoquine",{"trials":778,"activeCount":99},[779],{"nctId":780,"briefTitle":781,"status":111,"phases":782,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":787,"interventions":788},"NCT00694694","Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.",[90],"2008-12","2009-02","2008-06",261,[15],[789,790],"azithromycin + artesunate","artemether-lumefantrine",{"trials":792,"activeCount":99},[793],{"nctId":794,"briefTitle":795,"status":111,"phases":796,"primaryCompletion":571,"completion":571,"start":797,"enrollment":798,"conditions":799,"interventions":801},"NCT02325180","Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia",[91],"2015-01",338,[800],"Malaria, Falciparum",[802,745],"Dihydroartemisinin-Piperaquine",{"trials":804,"activeCount":99},[],{"intervention":806,"totalTrials":95,"cells":807},"artesunate-amodiaquine",{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":814,"PHASE4":826,"NA":838},{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[],{"trials":813,"activeCount":99},[],{"trials":815,"activeCount":99},[816],{"nctId":817,"briefTitle":818,"status":111,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":824},"NCT00119132","Effectiveness of Intermittent Preventive Treatment for Malaria in Children",[89,90],"2006-12","2005-06",2602,[15],[806,825],"sulphadoxine-pyrimethamine",{"trials":827,"activeCount":99},[828],{"nctId":829,"briefTitle":830,"status":111,"phases":831,"completion":832,"start":821,"enrollment":833,"conditions":834,"interventions":835},"NCT00119145","Kintampo Trial of Combination Therapy for Malaria",[91],"2006-05",510,[15],[806,836,837],"coartem","artesunate-lapdap",{"trials":839,"activeCount":99},[],{"intervention":841,"totalTrials":129,"cells":842},"Administration of Albendazole on Day 1",{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":867},{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[],{"trials":852,"activeCount":99},[853],{"nctId":854,"briefTitle":855,"status":111,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":863},"NCT03570814","Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin",[91],"2022-02-01","2021-12-01",13511,[861,862],"Trachoma","Lymphatic Filariases",[841,864,865,866],"Administration of Ivermectin on Day 1","Administration of Azithromycin on Day 1","Administration of Azithromycin on Day 15",{"trials":868,"activeCount":99},[],{"intervention":864,"totalTrials":129,"cells":870},{"EARLY_PHASE1":871,"PHASE1":873,"PHASE2":875,"PHASE3":877,"PHASE4":879,"NA":885},{"trials":872,"activeCount":99},[],{"trials":874,"activeCount":99},[],{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[881],{"nctId":854,"briefTitle":855,"status":111,"phases":882,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":883,"interventions":884},[91],[861,862],[841,864,865,866],{"trials":886,"activeCount":99},[],{"intervention":865,"totalTrials":129,"cells":888},{"EARLY_PHASE1":889,"PHASE1":891,"PHASE2":893,"PHASE3":895,"PHASE4":897,"NA":903},{"trials":890,"activeCount":99},[],{"trials":892,"activeCount":99},[],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[899],{"nctId":854,"briefTitle":855,"status":111,"phases":900,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":901,"interventions":902},[91],[861,862],[841,864,865,866],{"trials":904,"activeCount":99},[],{"intervention":866,"totalTrials":129,"cells":906},{"EARLY_PHASE1":907,"PHASE1":909,"PHASE2":911,"PHASE3":913,"PHASE4":915,"NA":921},{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[917],{"nctId":854,"briefTitle":855,"status":111,"phases":918,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":919,"interventions":920},[91],[861,862],[841,864,865,866],{"trials":922,"activeCount":99},[],{"intervention":924,"totalTrials":129,"cells":925},"Boostrix IPV infant acellular Pertussis",{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":934,"NA":949},{"trials":927,"activeCount":99},[],{"trials":929,"activeCount":99},[],{"trials":931,"activeCount":99},[],{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[936],{"nctId":937,"briefTitle":938,"status":457,"phases":939,"primaryCompletion":940,"completion":941,"start":942,"enrollment":462,"conditions":943,"interventions":945},"NCT03606096","Gambia Pertussis Study (GaPs)",[91],"2022-05-18","2022-12","2019-01-23",[944],"Pertussis",[924,946,947,948],"Boostrix IPV infant whole Pertussis","TT infant acellular Pertussis","TT infant whole Pertussis",{"trials":950,"activeCount":99},[],{"intervention":946,"totalTrials":129,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":959,"PHASE4":961,"NA":967},{"trials":954,"activeCount":99},[],{"trials":956,"activeCount":99},[],{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":99},[],{"trials":962,"activeCount":99},[963],{"nctId":937,"briefTitle":938,"status":457,"phases":964,"primaryCompletion":940,"completion":941,"start":942,"enrollment":462,"conditions":965,"interventions":966},[91],[944],[924,946,947,948],{"trials":968,"activeCount":99},[],{"intervention":947,"totalTrials":129,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":977,"PHASE4":979,"NA":985},{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"trials":978,"activeCount":99},[],{"trials":980,"activeCount":99},[981],{"nctId":937,"briefTitle":938,"status":457,"phases":982,"primaryCompletion":940,"completion":941,"start":942,"enrollment":462,"conditions":983,"interventions":984},[91],[944],[924,946,947,948],{"trials":986,"activeCount":99},[],{"intervention":948,"totalTrials":129,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":995,"PHASE4":997,"NA":1003},{"trials":990,"activeCount":99},[],{"trials":992,"activeCount":99},[],{"trials":994,"activeCount":99},[],{"trials":996,"activeCount":99},[],{"trials":998,"activeCount":99},[999],{"nctId":937,"briefTitle":938,"status":457,"phases":1000,"primaryCompletion":940,"completion":941,"start":942,"enrollment":462,"conditions":1001,"interventions":1002},[91],[944],[924,946,947,948],{"trials":1004,"activeCount":99},[],{"intervention":1006,"totalTrials":129,"cells":1007},"Intermittent screening and treatment of malaria in pregnancy",{"EARLY_PHASE1":1008,"PHASE1":1010,"PHASE2":1012,"PHASE3":1014,"PHASE4":1016,"NA":1028},{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[1018],{"nctId":1019,"briefTitle":1020,"status":111,"phases":1021,"primaryCompletion":214,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1026},"NCT01084213","Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy",[91],"2012-10","2010-06",5354,[15,30,18],[1006,1027],"SP-IPTp",{"trials":1029,"activeCount":99},[],{"intervention":1027,"totalTrials":129,"cells":1031},{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1046},{"trials":1033,"activeCount":99},[],{"trials":1035,"activeCount":99},[],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":99},[1042],{"nctId":1019,"briefTitle":1020,"status":111,"phases":1043,"primaryCompletion":214,"completion":1022,"start":1023,"enrollment":1024,"conditions":1044,"interventions":1045},[91],[15,30,18],[1006,1027],{"trials":1047,"activeCount":99},[],{"intervention":1049,"totalTrials":129,"cells":1050},"PCV10",{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1075},{"trials":1052,"activeCount":99},[],{"trials":1054,"activeCount":99},[],{"trials":1056,"activeCount":99},[],{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[1061],{"nctId":1062,"briefTitle":1063,"status":111,"phases":1064,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1069,"interventions":1073},"NCT03489018","The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants",[91],"2022-09-30","2024-11-01","2019-03-21",2100,[1070,1071,1072],"Pneumococcal Infection","Streptococcus Pneumoniae Infection","Invasive Pneumococcal Disease, Protection Against",[1049,1074],"PCV13",{"trials":1076,"activeCount":99},[],{"intervention":1074,"totalTrials":129,"cells":1078},{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1085,"PHASE4":1087,"NA":1093},{"trials":1080,"activeCount":99},[],{"trials":1082,"activeCount":99},[],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[1089],{"nctId":1062,"briefTitle":1063,"status":111,"phases":1090,"primaryCompletion":1065,"completion":1066,"start":1067,"enrollment":1068,"conditions":1091,"interventions":1092},[91],[1070,1071,1072],[1049,1074],{"trials":1094,"activeCount":99},[],{"intervention":601,"totalTrials":129,"cells":1096},{"EARLY_PHASE1":1097,"PHASE1":1099,"PHASE2":1101,"PHASE3":1103,"PHASE4":1105,"NA":1111},{"trials":1098,"activeCount":99},[],{"trials":1100,"activeCount":99},[],{"trials":1102,"activeCount":99},[],{"trials":1104,"activeCount":99},[],{"trials":1106,"activeCount":99},[1107],{"nctId":589,"briefTitle":590,"status":111,"phases":1108,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":1109,"interventions":1110},[91],[597,574,598],[600,386,601],{"trials":1112,"activeCount":99},[],{"intervention":1114,"totalTrials":129,"cells":1115},"IPV IM Needle",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1124,"NA":1139},{"trials":1117,"activeCount":99},[],{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[1126],{"nctId":1127,"briefTitle":1128,"status":111,"phases":1129,"primaryCompletion":1130,"completion":1131,"start":204,"enrollment":1132,"conditions":1133,"interventions":1135},"NCT01847872","IPV Clinical Trial - The Gambia",[91],"2015-04","2015-07",1504,[1134],"Poliomyelitis",[1114,1136,1137,1138],"IPV ID Needle","IPV IM Device","IPV ID Device",{"trials":1140,"activeCount":99},[],{"intervention":1136,"totalTrials":129,"cells":1142},{"EARLY_PHASE1":1143,"PHASE1":1145,"PHASE2":1147,"PHASE3":1149,"PHASE4":1151,"NA":1157},{"trials":1144,"activeCount":99},[],{"trials":1146,"activeCount":99},[],{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":99},[1153],{"nctId":1127,"briefTitle":1128,"status":111,"phases":1154,"primaryCompletion":1130,"completion":1131,"start":204,"enrollment":1132,"conditions":1155,"interventions":1156},[91],[1134],[1114,1136,1137,1138],{"trials":1158,"activeCount":99},[],{"intervention":1137,"totalTrials":129,"cells":1160},{"EARLY_PHASE1":1161,"PHASE1":1163,"PHASE2":1165,"PHASE3":1167,"PHASE4":1169,"NA":1175},{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":99},[],{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":99},[1171],{"nctId":1127,"briefTitle":1128,"status":111,"phases":1172,"primaryCompletion":1130,"completion":1131,"start":204,"enrollment":1132,"conditions":1173,"interventions":1174},[91],[1134],[1114,1136,1137,1138],{"trials":1176,"activeCount":99},[],{"intervention":1138,"totalTrials":129,"cells":1178},{"EARLY_PHASE1":1179,"PHASE1":1181,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1193},{"trials":1180,"activeCount":99},[],{"trials":1182,"activeCount":99},[],{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":99},[],{"trials":1188,"activeCount":99},[1189],{"nctId":1127,"briefTitle":1128,"status":111,"phases":1190,"primaryCompletion":1130,"completion":1131,"start":204,"enrollment":1132,"conditions":1191,"interventions":1192},[91],[1134],[1114,1136,1137,1138],{"trials":1194,"activeCount":99},[],{"intervention":1196,"totalTrials":129,"cells":1197},"Norethisterone enantate",{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1202,"PHASE3":1204,"PHASE4":1206,"NA":1219},{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":99},[],{"trials":1203,"activeCount":99},[],{"trials":1205,"activeCount":99},[],{"trials":1207,"activeCount":99},[1208],{"nctId":1209,"briefTitle":1210,"status":111,"phases":1211,"primaryCompletion":1212,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1218},"NCT02905890","The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis",[91],"2019-12-20","2017-10-02",250,[1216,1217],"Bacterial Vaginosis","HIV",[1196],{"trials":1220,"activeCount":99},[],{"intervention":1222,"totalTrials":129,"cells":1223},"Atorvastatin 20mg",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1244},{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"trials":1231,"activeCount":99},[],{"trials":1233,"activeCount":99},[1234],{"nctId":1235,"briefTitle":1236,"status":111,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":1240,"conditions":1241,"interventions":1243},"NCT02781064","STATIN: Web-based Investigation of Side Effects",[91],"2019-08-08","2016-09-01",200,[1242],"Cardiovascular Disease",[1222],{"trials":1245,"activeCount":99},[],{"intervention":1247,"totalTrials":129,"cells":1248},"NSAI treatment",{"EARLY_PHASE1":1249,"PHASE1":1251,"PHASE2":1253,"PHASE3":1255,"PHASE4":1257,"NA":1269},{"trials":1250,"activeCount":99},[],{"trials":1252,"activeCount":99},[],{"trials":1254,"activeCount":99},[],{"trials":1256,"activeCount":99},[],{"trials":1258,"activeCount":99},[1259],{"nctId":1260,"briefTitle":1261,"status":111,"phases":1262,"primaryCompletion":700,"completion":700,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1267},"NCT01452997","Evaluation of Anti-inflammatories in the Reduction of Bite Reactions",[91],"2012-11",40,[1266],"Mosquito Bite",[1247,1268],"Steroid treatment",{"trials":1270,"activeCount":99},[],{"intervention":1268,"totalTrials":129,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1277,"PHASE3":1279,"PHASE4":1281,"NA":1287},{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[],{"trials":1280,"activeCount":99},[],{"trials":1282,"activeCount":99},[1283],{"nctId":1260,"briefTitle":1261,"status":111,"phases":1284,"primaryCompletion":700,"completion":700,"start":1263,"enrollment":1264,"conditions":1285,"interventions":1286},[91],[1266],[1247,1268],{"trials":1288,"activeCount":99},[],{"intervention":613,"totalTrials":129,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1297,"PHASE4":1299,"NA":1305},{"trials":1292,"activeCount":99},[],{"trials":1294,"activeCount":99},[],{"trials":1296,"activeCount":99},[],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[1301],{"nctId":603,"briefTitle":604,"status":111,"phases":1302,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":1303,"interventions":1304},[91],[611],[613,386],{"trials":1306,"activeCount":99},[],{"intervention":836,"totalTrials":129,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1315,"PHASE4":1317,"NA":1323},{"trials":1310,"activeCount":99},[],{"trials":1312,"activeCount":99},[],{"trials":1314,"activeCount":99},[],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[1319],{"nctId":829,"briefTitle":830,"status":111,"phases":1320,"completion":832,"start":821,"enrollment":833,"conditions":1321,"interventions":1322},[91],[15],[806,836,837],{"trials":1324,"activeCount":99},[],{"intervention":837,"totalTrials":129,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1335,"NA":1341},{"trials":1328,"activeCount":99},[],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"trials":1334,"activeCount":99},[],{"trials":1336,"activeCount":99},[1337],{"nctId":829,"briefTitle":830,"status":111,"phases":1338,"completion":832,"start":821,"enrollment":833,"conditions":1339,"interventions":1340},[91],[15],[806,836,837],{"trials":1342,"activeCount":99},[],{"intervention":1344,"totalTrials":129,"cells":1345},"sulfadoxine \u002Fpyrimethamine plus amodiaquine",{"EARLY_PHASE1":1346,"PHASE1":1348,"PHASE2":1350,"PHASE3":1352,"PHASE4":1354,"NA":1364},{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[1356],{"nctId":1357,"briefTitle":1358,"status":111,"phases":1359,"completion":1360,"start":832,"enrollment":1361,"conditions":1362,"interventions":1363},"NCT00376155","Comparison of Two Strategies for the Delivery of IPTc",[91],"2007-02",14000,[15],[1344],{"trials":1365,"activeCount":99},[],{"intervention":1367,"totalTrials":129,"cells":1368},"MenAfriVac™",{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1377,"NA":1390},{"trials":1370,"activeCount":99},[],{"trials":1372,"activeCount":99},[],{"trials":1374,"activeCount":99},[],{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[1379],{"nctId":1380,"briefTitle":1381,"status":111,"phases":1382,"primaryCompletion":1383,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1389},"NCT01119482","Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage",[91],"2012-05","2012-06","2010-05",33000,[1388],"Meningitis",[1367],{"trials":1391,"activeCount":99},[],{"intervention":1393,"totalTrials":475,"cells":1394},"Primaquine",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1399,"PHASE3":1414,"PHASE4":1447,"NA":1449},{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":99},[],{"trials":1400,"activeCount":99},[1401],{"nctId":1402,"briefTitle":1403,"status":111,"phases":1404,"primaryCompletion":821,"completion":1405,"start":1406,"enrollment":1407,"conditions":1408,"interventions":1410},"NCT00959517","Trial of Artesunate Combination Therapy in Pakistan",[89],"2006-08","2001-07",588,[1409],"Uncomplicated Falciparum Malaria",[1411,825,1412,1413],"artesunate","Chloroquine","primaquine",{"trials":1415,"activeCount":99},[1416,1426,1438],{"nctId":1417,"briefTitle":1418,"status":111,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":737,"enrollment":1422,"conditions":1423,"interventions":1425},"NCT01365598","Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda",[90],"2013-03","2013-05",468,[1424],"Falciparum Malaria",[1393],{"nctId":1427,"briefTitle":1428,"status":111,"phases":1429,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":1434,"interventions":1436},"NCT02259426","Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission",[90],"2015-09","2015-12","2014-10",120,[15,1435,347],"Asymptomatic Malaria",[1437,1393],"Dihydroartemisinin-piperaquine combination",{"nctId":1439,"briefTitle":1440,"status":111,"phases":1441,"completion":1442,"start":1443,"enrollment":714,"conditions":1444,"interventions":1446},"NCT00158587","Eight Week Primaquine Regimen for the Treatment of Vivax Malaria",[90],"2007-03","2004-04",[15,1445],"Vivax Malaria",[1413],{"trials":1448,"activeCount":99},[],{"trials":1450,"activeCount":99},[],{"intervention":492,"totalTrials":475,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1475,"PHASE4":1481,"NA":1483},{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":99},[1459,1467,1471],{"nctId":1460,"briefTitle":1461,"status":111,"phases":1462,"primaryCompletion":1463,"completion":204,"start":114,"enrollment":1464,"conditions":1465,"interventions":1466},"NCT00919451","Ciclosporin in the Management of Steroid Resistant Type 1 Reactions in Leprosy",[89],"2013-06",16,[490],[492],{"nctId":484,"briefTitle":485,"status":111,"phases":1468,"primaryCompletion":487,"completion":204,"start":114,"enrollment":488,"conditions":1469,"interventions":1470},[89],[490],[474,492],{"nctId":494,"briefTitle":495,"status":111,"phases":1472,"primaryCompletion":487,"completion":204,"start":497,"enrollment":19,"conditions":1473,"interventions":1474},[89],[490],[500,474],{"trials":1476,"activeCount":99},[1477],{"nctId":504,"briefTitle":505,"status":111,"phases":1478,"primaryCompletion":487,"completion":204,"start":114,"enrollment":507,"conditions":1479,"interventions":1480},[89,90],[490],[500,510],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"intervention":1486,"totalTrials":428,"cells":1487},"Artemether-lumefantrine combination",{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1503,"PHASE4":1524,"NA":1526},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":99},[1494],{"nctId":1495,"briefTitle":1496,"status":111,"phases":1497,"primaryCompletion":700,"completion":700,"start":1498,"enrollment":1433,"conditions":1499,"interventions":1500},"NCT01603251","Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission",[88,89],"2013-01",[15],[1486,1501,1502],"Artemether-lumefantrine combination + single dose Ivermectin","Artemether-lumefantrine combination + repeated dose Ivermectin",{"trials":1504,"activeCount":99},[1505,1515],{"nctId":1506,"briefTitle":1507,"status":111,"phases":1508,"primaryCompletion":1131,"completion":1131,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1512},"NCT01935882","Low Dose Primaquine for Clearance of Gametocytes",[89,90],"2013-09",360,[15,1435,347],[1486,1513,1514],"Artemether-Lumefantrine with a single dose of 0.25mg\u002Fkg primaquine","Artemether-Lumefantrine with a single dose of 0.4mg\u002Fkg primaquine",{"nctId":1516,"briefTitle":1517,"status":111,"phases":1518,"primaryCompletion":1519,"completion":1519,"start":700,"enrollment":1520,"conditions":1521,"interventions":1522},"NCT01939886","Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)",[90],"2013-11",219,[15],[1523,1486],"Mefloquine - Artesunate",{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[],{"intervention":1529,"totalTrials":428,"cells":1530},"Chlorproguanil-dapsone",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1537,"PHASE4":1573,"NA":1575},{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[1539,1547,1560],{"nctId":1540,"briefTitle":1541,"status":111,"phases":1542,"completion":821,"start":1543,"enrollment":674,"conditions":1544,"interventions":1545},"NCT00118794","Lapdap and Coartemether for Uncomplicated Malaria",[90],"2004-09",[15],[1529,1546],"Lumefantrine-artemether",{"nctId":1548,"briefTitle":1549,"status":111,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1554,"interventions":1555},"NCT00146731","A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania",[90],"2007-09","2004-01",310,[15],[1556,1557,1558,1559],"SP","SP + amodiaquine","AQ + artesunate","chlorproguanil-dapsone",{"nctId":1561,"briefTitle":1562,"status":111,"phases":1563,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1568},"NCT00158574","Kilimanjaro IPTi Drug Options Trial",[89,90],"2008-04","2005-01",2419,[15],[825,1569,1529,1570,1571,1572],"mefloquine","Sulphadoxine-pryrimethamine","IPTi mefloquine","Chlorproguanil dapsone",{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"intervention":1556,"totalTrials":428,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1583,"PHASE3":1585,"PHASE4":1611,"NA":1613},{"trials":1580,"activeCount":99},[],{"trials":1582,"activeCount":99},[],{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[1587,1599,1603],{"nctId":1588,"briefTitle":1589,"status":111,"phases":1590,"primaryCompletion":1591,"completion":1592,"start":1593,"enrollment":1594,"conditions":1595,"interventions":1596},"NCT06173206","Parasite Clearance and Protection From Infection (PCPI) in Cameroon",[90],"2024-12-25","2025-03-05","2024-06-10",902,[15],[1556,1597,1598],"SPAQ","AS",{"nctId":1548,"briefTitle":1549,"status":111,"phases":1600,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":1601,"interventions":1602},[90],[15],[1556,1557,1558,1559],{"nctId":1604,"briefTitle":1605,"status":111,"phases":1606,"primaryCompletion":1607,"completion":1592,"start":1608,"enrollment":462,"conditions":1609,"interventions":1610},"NCT06166498","Parasite Clearance and Protection From Infection (PCPI) in Zambia",[90],"2024-12-19","2024-07-24",[15],[1556,1598],{"trials":1612,"activeCount":99},[],{"trials":1614,"activeCount":99},[],{"intervention":1616,"totalTrials":95,"cells":1617},"Dihydroartemisinin\u002FPiperaquine",{"EARLY_PHASE1":1618,"PHASE1":1620,"PHASE2":1622,"PHASE3":1634,"PHASE4":1646,"NA":1648},{"trials":1619,"activeCount":99},[],{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[1624],{"nctId":1625,"briefTitle":1626,"status":111,"phases":1627,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":772,"conditions":1631,"interventions":1632},"NCT04609098","Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)",[89],"2020-12-02","2020-12-23","2020-10-29",[800],[1616,1633],"Tafenoquine 100mg [Arakoda]",{"trials":1635,"activeCount":99},[1636],{"nctId":1637,"briefTitle":1638,"status":111,"phases":1639,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":760,"conditions":1642,"interventions":1643},"NCT04049916","Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission",[89,90],"2020-01-07","2019-09-12",[32],[1644,1616,1645],"Pyronaridine Tetraphosphate\u002FArtesunate","Primaquine Diphosphate",{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[],{"intervention":1651,"totalTrials":95,"cells":1652},"BCG",{"EARLY_PHASE1":1653,"PHASE1":1655,"PHASE2":1657,"PHASE3":1667,"PHASE4":1677,"NA":1679},{"trials":1654,"activeCount":99},[],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[1659],{"nctId":1660,"briefTitle":1661,"status":111,"phases":1662,"conditions":1663,"interventions":1666},"NCT00241657","Immune Responses to BCG Vaccination in Malawi and the UK",[89],[1664,1665],"Immunity, Cellular","Hypersensitivity, Delayed Type",[1651],{"trials":1668,"activeCount":99},[1669],{"nctId":1670,"briefTitle":1671,"status":111,"phases":1672,"completion":1673,"start":1674,"enrollment":674,"conditions":1675,"interventions":1676},"NCT00131794","Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria",[90],"2003-12","2003-01",[15],[1651],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[],{"intervention":1682,"totalTrials":95,"cells":1683},"SMC with SP+AQ",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1688,"PHASE3":1690,"PHASE4":1716,"NA":1718},{"trials":1685,"activeCount":99},[],{"trials":1687,"activeCount":99},[],{"trials":1689,"activeCount":99},[],{"trials":1691,"activeCount":99},[1692,1705],{"nctId":1693,"briefTitle":1694,"status":111,"phases":1695,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT04319380","Seasonal Malaria Vaccination (RTS,S\u002FAS01) and Seasonal Malaria Chemoprevention (SP\u002FAQ) Extension Study",[90],"2022-03-31","2020-04-01",5098,[32,1700],"Child, Only",[1702,1682,1703,1704],"Tetanus\u002Fdiphtheria toxoids","RTS,S\u002FAS01","SMC placebo",{"nctId":1706,"briefTitle":1707,"status":111,"phases":1708,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":1712,"interventions":1714},"NCT03143218","Seasonal Malaria Vaccination (RTS,S\u002FAS01) and Seasonal Malaria Chemoprevention (SP\u002FAQ)",[90],"2020-03-31","2017-04-17",5920,[32,1713],"Children, Only",[1715,1703,1682,1704],"RABIPUR®",{"trials":1717,"activeCount":99},[],{"trials":1719,"activeCount":99},[],{"intervention":1703,"totalTrials":95,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1726,"PHASE3":1728,"PHASE4":1738,"NA":1740},{"trials":1723,"activeCount":99},[],{"trials":1725,"activeCount":99},[],{"trials":1727,"activeCount":99},[],{"trials":1729,"activeCount":99},[1730,1734],{"nctId":1693,"briefTitle":1694,"status":111,"phases":1731,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":1732,"interventions":1733},[90],[32,1700],[1702,1682,1703,1704],{"nctId":1706,"briefTitle":1707,"status":111,"phases":1735,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":1736,"interventions":1737},[90],[32,1713],[1715,1703,1682,1704],{"trials":1739,"activeCount":99},[],{"trials":1741,"activeCount":99},[],{"intervention":1704,"totalTrials":95,"cells":1743},{"EARLY_PHASE1":1744,"PHASE1":1746,"PHASE2":1748,"PHASE3":1750,"PHASE4":1760,"NA":1762},{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[],{"trials":1749,"activeCount":99},[],{"trials":1751,"activeCount":99},[1752,1756],{"nctId":1693,"briefTitle":1694,"status":111,"phases":1753,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":1754,"interventions":1755},[90],[32,1700],[1702,1682,1703,1704],{"nctId":1706,"briefTitle":1707,"status":111,"phases":1757,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":1758,"interventions":1759},[90],[32,1713],[1715,1703,1682,1704],{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[],{"intervention":1411,"totalTrials":95,"cells":1765},{"EARLY_PHASE1":1766,"PHASE1":1768,"PHASE2":1770,"PHASE3":1776,"PHASE4":1789,"NA":1791},{"trials":1767,"activeCount":99},[],{"trials":1769,"activeCount":99},[],{"trials":1771,"activeCount":99},[1772],{"nctId":1402,"briefTitle":1403,"status":111,"phases":1773,"primaryCompletion":821,"completion":1405,"start":1406,"enrollment":1407,"conditions":1774,"interventions":1775},[89],[1409],[1411,825,1412,1413],{"trials":1777,"activeCount":99},[1778],{"nctId":1779,"briefTitle":1780,"status":111,"phases":1781,"completion":1782,"start":1783,"enrollment":1784,"conditions":1785,"interventions":1786},"NCT00132548","A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children",[90],"2004-12","2004-06",2200,[15],[1787,472,1788],"Pyrimethamine\u002Fsulfadoxine","Artesunate",{"trials":1790,"activeCount":99},[],{"trials":1792,"activeCount":99},[],{"intervention":1794,"totalTrials":95,"cells":1795},"Intermittent preventive treatment",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1802,"PHASE4":1824,"NA":1826},{"trials":1797,"activeCount":99},[],{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[1804,1812],{"nctId":1805,"briefTitle":1806,"status":111,"phases":1807,"primaryCompletion":1808,"completion":1808,"start":1565,"enrollment":1809,"conditions":1810,"interventions":1811},"NCT00142246","Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.",[90],"2006-04",6758,[800],[1794],{"nctId":1813,"briefTitle":1814,"status":111,"phases":1815,"primaryCompletion":1816,"completion":785,"start":1817,"enrollment":1818,"conditions":1819,"interventions":1820},"NCT00561899","Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children",[89,90],"2008-02","2007-08",1295,[15],[1821,1822,1823],"SP, amodiaquine, piperaquine, dihdroartemisinin","intermittent preventive treatment","Du-Cotecxin",{"trials":1825,"activeCount":99},[],{"trials":1827,"activeCount":99},[],{"intervention":1598,"totalTrials":95,"cells":1829},{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1846,"NA":1848},{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[1838,1842],{"nctId":1588,"briefTitle":1589,"status":111,"phases":1839,"primaryCompletion":1591,"completion":1592,"start":1593,"enrollment":1594,"conditions":1840,"interventions":1841},[90],[15],[1556,1597,1598],{"nctId":1604,"briefTitle":1605,"status":111,"phases":1843,"primaryCompletion":1607,"completion":1592,"start":1608,"enrollment":462,"conditions":1844,"interventions":1845},[90],[15],[1556,1598],{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[],{"intervention":1851,"totalTrials":129,"cells":1852},"DHA-PPQ",{"EARLY_PHASE1":1853,"PHASE1":1855,"PHASE2":1857,"PHASE3":1859,"PHASE4":1872,"NA":1874},{"trials":1854,"activeCount":99},[],{"trials":1856,"activeCount":99},[],{"trials":1858,"activeCount":99},[],{"trials":1860,"activeCount":99},[1861],{"nctId":1862,"briefTitle":1863,"status":111,"phases":1864,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":1868,"conditions":1869,"interventions":1870},"NCT01838902","Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers",[90],"2015-02","2015-10","2013-08",467,[15],[1851,1871,1871,1871],"PQ",{"trials":1873,"activeCount":99},[],{"trials":1875,"activeCount":99},[],{"intervention":1871,"totalTrials":129,"cells":1877},{"EARLY_PHASE1":1878,"PHASE1":1880,"PHASE2":1882,"PHASE3":1884,"PHASE4":1890,"NA":1892},{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"trials":1883,"activeCount":99},[],{"trials":1885,"activeCount":99},[1886],{"nctId":1862,"briefTitle":1863,"status":111,"phases":1887,"primaryCompletion":1865,"completion":1866,"start":1867,"enrollment":1868,"conditions":1888,"interventions":1889},[90],[15],[1851,1871,1871,1871],{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"intervention":1895,"totalTrials":129,"cells":1896},"Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1903,"PHASE4":1918,"NA":1920},{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[],{"trials":1904,"activeCount":99},[1905],{"nctId":1906,"briefTitle":1907,"status":1908,"phases":1909,"primaryCompletion":1910,"completion":570,"start":1431,"enrollment":1911,"conditions":1912,"interventions":1913},"NCT02654730","Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia","TERMINATED",[89,90],"2016-09",61,[15],[1895,1914,1915,1916,1917],"Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg\u002Fkg primaquine administered to G6PD deficient","Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg\u002Fkg primaquine administered to G6PD deficient","Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg\u002Fkg primaquine administered to G6PD normal","Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg\u002Fkg primaquine administered to G6PD normal",{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"intervention":1914,"totalTrials":129,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1936,"NA":1938},{"trials":1925,"activeCount":99},[],{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[],{"trials":1931,"activeCount":99},[1932],{"nctId":1906,"briefTitle":1907,"status":1908,"phases":1933,"primaryCompletion":1910,"completion":570,"start":1431,"enrollment":1911,"conditions":1934,"interventions":1935},[89,90],[15],[1895,1914,1915,1916,1917],{"trials":1937,"activeCount":99},[],{"trials":1939,"activeCount":99},[],{"intervention":1915,"totalTrials":129,"cells":1941},{"EARLY_PHASE1":1942,"PHASE1":1944,"PHASE2":1946,"PHASE3":1948,"PHASE4":1954,"NA":1956},{"trials":1943,"activeCount":99},[],{"trials":1945,"activeCount":99},[],{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[1950],{"nctId":1906,"briefTitle":1907,"status":1908,"phases":1951,"primaryCompletion":1910,"completion":570,"start":1431,"enrollment":1911,"conditions":1952,"interventions":1953},[89,90],[15],[1895,1914,1915,1916,1917],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"intervention":1916,"totalTrials":129,"cells":1959},{"EARLY_PHASE1":1960,"PHASE1":1962,"PHASE2":1964,"PHASE3":1966,"PHASE4":1972,"NA":1974},{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[],{"trials":1965,"activeCount":99},[],{"trials":1967,"activeCount":99},[1968],{"nctId":1906,"briefTitle":1907,"status":1908,"phases":1969,"primaryCompletion":1910,"completion":570,"start":1431,"enrollment":1911,"conditions":1970,"interventions":1971},[89,90],[15],[1895,1914,1915,1916,1917],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"intervention":1917,"totalTrials":129,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1984,"PHASE4":1990,"NA":1992},{"trials":1979,"activeCount":99},[],{"trials":1981,"activeCount":99},[],{"trials":1983,"activeCount":99},[],{"trials":1985,"activeCount":99},[1986],{"nctId":1906,"briefTitle":1907,"status":1908,"phases":1987,"primaryCompletion":1910,"completion":570,"start":1431,"enrollment":1911,"conditions":1988,"interventions":1989},[89,90],[15],[1895,1914,1915,1916,1917],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[],{"intervention":1995,"totalTrials":129,"cells":1996},"Folic acid",{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2001,"PHASE3":2003,"PHASE4":2013,"NA":2015},{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"trials":2004,"activeCount":99},[2005],{"nctId":2006,"briefTitle":2007,"status":111,"phases":2008,"completion":1552,"start":2009,"enrollment":2010,"conditions":2011,"interventions":2012},"NCT00120822","Folic Acid Supplementation in Gambian Primigravidae",[90],"2002-07",1000,[15],[1995],{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"intervention":2018,"totalTrials":129,"cells":2019},"Ad26.ZEBOV, MVA-BN-Filo vaccine",{"EARLY_PHASE1":2020,"PHASE1":2022,"PHASE2":2024,"PHASE3":2026,"PHASE4":2039,"NA":2041},{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[2028],{"nctId":2029,"briefTitle":2030,"status":457,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT04152486","Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC",[90],"2022-01-31","2022-02-28","2019-11-14",20426,[2037],"Ebola Virus Disease",[2018],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"intervention":2044,"totalTrials":129,"cells":2045},"17D Yellow fever vaccine",{"EARLY_PHASE1":2046,"PHASE1":2048,"PHASE2":2050,"PHASE3":2052,"PHASE4":2064,"NA":2066},{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[2054],{"nctId":2055,"briefTitle":2056,"status":457,"phases":2057,"primaryCompletion":2058,"completion":460,"start":2059,"enrollment":2060,"conditions":2061,"interventions":2063},"NCT05332197","Booster Vaccine for Yellow Fever",[90],"2023-06","2022-05-16",750,[2062],"Yellow Fever",[2044],{"trials":2065,"activeCount":99},[],{"trials":2067,"activeCount":99},[],{"intervention":2069,"totalTrials":129,"cells":2070},"Sulfadoxine\u002Fpyrimethamine and artesunate",{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2075,"PHASE3":2077,"PHASE4":2086,"NA":2088},{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[2079],{"nctId":2080,"briefTitle":2081,"status":111,"phases":2082,"completion":1673,"start":2083,"enrollment":674,"conditions":2084,"interventions":2085},"NCT00132561","A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children",[89,90],"2002-06",[15],[2069],{"trials":2087,"activeCount":99},[],{"trials":2089,"activeCount":99},[],{"intervention":2091,"totalTrials":129,"cells":2092},"sulfadoxine-pyrimethamine and chlorproguanil-dapsone",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2108,"NA":2110},{"trials":2094,"activeCount":99},[],{"trials":2096,"activeCount":99},[],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[2101],{"nctId":2102,"briefTitle":2103,"status":111,"phases":2104,"completion":2105,"start":724,"enrollment":2060,"conditions":2106,"interventions":2107},"NCT00158561","Chlorproguanil\u002FDapsone Compared With Chloroquine and SP for Vivax Malaria",[90],"2006-03",[15,1445],[2091],{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"intervention":2113,"totalTrials":129,"cells":2114},"1. Artemether-Lumefantrine",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2121,"PHASE4":2134,"NA":2136},{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[],{"trials":2122,"activeCount":99},[2123],{"nctId":2124,"briefTitle":2125,"status":111,"phases":2126,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":2130,"conditions":2131,"interventions":2132},"NCT00297882","Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon",[90],"2009-04","2009-07","2006-07",816,[15],[2113,2133],"2. Amodiaquine-Artesunate",{"trials":2135,"activeCount":99},[],{"trials":2137,"activeCount":99},[],{"intervention":2133,"totalTrials":129,"cells":2139},{"EARLY_PHASE1":2140,"PHASE1":2142,"PHASE2":2144,"PHASE3":2146,"PHASE4":2152,"NA":2154},{"trials":2141,"activeCount":99},[],{"trials":2143,"activeCount":99},[],{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[2148],{"nctId":2124,"briefTitle":2125,"status":111,"phases":2149,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":2130,"conditions":2150,"interventions":2151},[90],[15],[2113,2133],{"trials":2153,"activeCount":99},[],{"trials":2155,"activeCount":99},[],{"intervention":1702,"totalTrials":129,"cells":2157},{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2170,"NA":2172},{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[],{"trials":2165,"activeCount":99},[2166],{"nctId":1693,"briefTitle":1694,"status":111,"phases":2167,"primaryCompletion":1696,"completion":1696,"start":1697,"enrollment":1698,"conditions":2168,"interventions":2169},[90],[32,1700],[1702,1682,1703,1704],{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"intervention":1513,"totalTrials":129,"cells":2175},{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2188,"NA":2190},{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":1506,"briefTitle":1507,"status":111,"phases":2185,"primaryCompletion":1131,"completion":1131,"start":1509,"enrollment":1510,"conditions":2186,"interventions":2187},[89,90],[15,1435,347],[1486,1513,1514],{"trials":2189,"activeCount":99},[],{"trials":2191,"activeCount":99},[],{"intervention":1514,"totalTrials":129,"cells":2193},{"EARLY_PHASE1":2194,"PHASE1":2196,"PHASE2":2198,"PHASE3":2200,"PHASE4":2206,"NA":2208},{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[],{"trials":2201,"activeCount":99},[2202],{"nctId":1506,"briefTitle":1507,"status":111,"phases":2203,"primaryCompletion":1131,"completion":1131,"start":1509,"enrollment":1510,"conditions":2204,"interventions":2205},[89,90],[15,1435,347],[1486,1513,1514],{"trials":2207,"activeCount":99},[],{"trials":2209,"activeCount":99},[],{"intervention":789,"totalTrials":129,"cells":2211},{"EARLY_PHASE1":2212,"PHASE1":2214,"PHASE2":2216,"PHASE3":2218,"PHASE4":2224,"NA":2226},{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[],{"trials":2219,"activeCount":99},[2220],{"nctId":780,"briefTitle":781,"status":111,"phases":2221,"primaryCompletion":783,"completion":784,"start":785,"enrollment":786,"conditions":2222,"interventions":2223},[90],[15],[789,790],{"trials":2225,"activeCount":99},[],{"trials":2227,"activeCount":99},[],{"intervention":2229,"totalTrials":129,"cells":2230},"Aspirin",{"EARLY_PHASE1":2231,"PHASE1":2233,"PHASE2":2235,"PHASE3":2237,"PHASE4":2251,"NA":2253},{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"trials":2238,"activeCount":99},[2239],{"nctId":2240,"briefTitle":2241,"status":2242,"phases":2243,"primaryCompletion":2244,"completion":2245,"start":2246,"enrollment":99,"conditions":2247,"interventions":2248},"NCT04343001","Coronavirus Response - Active Support for Hospitalised Covid-19 Patients","WITHDRAWN",[90],"2021-04","2021-08","2020-10",[676],[2229,2249,2250],"Losartan","Simvastatin",{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"intervention":2249,"totalTrials":129,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2263,"PHASE4":2269,"NA":2271},{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[2265],{"nctId":2240,"briefTitle":2241,"status":2242,"phases":2266,"primaryCompletion":2244,"completion":2245,"start":2246,"enrollment":99,"conditions":2267,"interventions":2268},[90],[676],[2229,2249,2250],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"intervention":2250,"totalTrials":129,"cells":2274},{"EARLY_PHASE1":2275,"PHASE1":2277,"PHASE2":2279,"PHASE3":2281,"PHASE4":2287,"NA":2289},{"trials":2276,"activeCount":99},[],{"trials":2278,"activeCount":99},[],{"trials":2280,"activeCount":99},[],{"trials":2282,"activeCount":99},[2283],{"nctId":2240,"briefTitle":2241,"status":2242,"phases":2284,"primaryCompletion":2244,"completion":2245,"start":2246,"enrollment":99,"conditions":2285,"interventions":2286},[90],[676],[2229,2249,2250],{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[],{"intervention":229,"totalTrials":129,"cells":2292},{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2305,"NA":2307},{"trials":2294,"activeCount":99},[],{"trials":2296,"activeCount":99},[],{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[2301],{"nctId":219,"briefTitle":220,"status":111,"phases":2302,"primaryCompletion":222,"completion":223,"start":224,"enrollment":225,"conditions":2303,"interventions":2304},[90],[227],[61,229],{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[],{"intervention":2310,"totalTrials":129,"cells":2311},"IPTp-sulphadoxine-pyrimethamine plus metronidazole",{"EARLY_PHASE1":2312,"PHASE1":2314,"PHASE2":2316,"PHASE3":2318,"PHASE4":2335,"NA":2337},{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":99},[],{"trials":2319,"activeCount":99},[2320],{"nctId":2321,"briefTitle":2322,"status":111,"phases":2323,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":2327,"conditions":2328,"interventions":2332},"NCT04189744","The ASPIRE Trial - Aiming for Safe Pregnancies by Reducing Malaria and Infections of the Reproductive Tract",[90],"2022-10-21","2023-03-31","2019-12-15",5436,[2329,2330,2331],"Pregnancy Malaria","Bacterial Vaginoses","Trichomonas Vaginitis",[2310,2333,2334],"IPTp-dihydroartemisinin-piperaquine plus metronidazole","IPTp-sulphadoxine-pyrimethamine",{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[],{"intervention":2333,"totalTrials":129,"cells":2340},{"EARLY_PHASE1":2341,"PHASE1":2343,"PHASE2":2345,"PHASE3":2347,"PHASE4":2353,"NA":2355},{"trials":2342,"activeCount":99},[],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[2349],{"nctId":2321,"briefTitle":2322,"status":111,"phases":2350,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":2327,"conditions":2351,"interventions":2352},[90],[2329,2330,2331],[2310,2333,2334],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[],{"intervention":2334,"totalTrials":129,"cells":2358},{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2371,"NA":2373},{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[2367],{"nctId":2321,"briefTitle":2322,"status":111,"phases":2368,"primaryCompletion":2324,"completion":2325,"start":2326,"enrollment":2327,"conditions":2369,"interventions":2370},[90],[2329,2330,2331],[2310,2333,2334],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[],{"intervention":2376,"totalTrials":129,"cells":2377},"20% deet insect repellent",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2382,"PHASE3":2384,"PHASE4":2396,"NA":2398},{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[2386],{"nctId":2387,"briefTitle":2388,"status":457,"phases":2389,"primaryCompletion":2390,"completion":2391,"start":2128,"enrollment":169,"conditions":2392,"interventions":2395},"NCT00938379","Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR",[90],"2010-12","2011-06",[15,2393,2394],"Dengue","Japanese Encephalitis",[2376],{"trials":2397,"activeCount":99},[],{"trials":2399,"activeCount":99},[],{"intervention":2401,"totalTrials":129,"cells":2402},"amodiaquine + sulfadoxine-pyrimethamine",{"EARLY_PHASE1":2403,"PHASE1":2405,"PHASE2":2407,"PHASE3":2409,"PHASE4":2420,"NA":2422},{"trials":2404,"activeCount":99},[],{"trials":2406,"activeCount":99},[],{"trials":2408,"activeCount":99},[],{"trials":2410,"activeCount":99},[2411],{"nctId":2412,"briefTitle":2413,"status":111,"phases":2414,"primaryCompletion":785,"completion":785,"start":1816,"enrollment":2415,"conditions":2416,"interventions":2418},"NCT00852371","Intermittent Preventive Treatment of Malaria in Schoolchildren",[90],780,[15,2417],"Intermittent Preventive Treatment",[2419,2401,637],"sulfadoxine-pyrimethamine",{"trials":2421,"activeCount":99},[],{"trials":2423,"activeCount":99},[],{"intervention":2425,"totalTrials":129,"cells":2426},"Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2433,"PHASE4":2443,"NA":2445},{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[2435],{"nctId":2436,"briefTitle":2437,"status":111,"phases":2438,"primaryCompletion":784,"completion":2439,"start":1360,"enrollment":2440,"conditions":2441,"interventions":2442},"NCT00432367","Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy",[90],"2009-09",3333,[15,18,30],[2425],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[],{"intervention":2448,"totalTrials":129,"cells":2449},"Sulfadoxine-pyrimethamine plus artesunate",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2456,"PHASE4":2468,"NA":2470},{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[2458],{"nctId":2459,"briefTitle":2460,"status":111,"phases":2461,"completion":2462,"start":2463,"enrollment":1510,"conditions":2464,"interventions":2466},"NCT00289250","Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum",[90],"2001-12","2001-05",[2465],"Asymptomatic P.Falciparum Malaria",[2467,2448],"Sulfadoxine-pyrimethamine",{"trials":2469,"activeCount":99},[],{"trials":2471,"activeCount":99},[],{"intervention":2473,"totalTrials":129,"cells":2474},"SP, chloroquine, amodiaquine, primaquine, artesunate",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2481,"PHASE4":2491,"NA":2493},{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":99},[2483],{"nctId":2484,"briefTitle":2485,"status":111,"phases":2486,"completion":1782,"start":2487,"enrollment":2488,"conditions":2489,"interventions":2490},"NCT00158548","ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan",[90],"2001-06",650,[15,1424,1445],[2473],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"intervention":2496,"totalTrials":129,"cells":2497},"13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2515,"NA":2517},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[2506],{"nctId":2507,"briefTitle":2508,"status":457,"phases":2509,"primaryCompletion":2510,"completion":2511,"start":2512,"enrollment":462,"conditions":2513,"interventions":2514},"NCT02628886","Protecting From Pneumococcus in Early Life (The PROPEL Trial)",[90],"2019-02-19","2020-12","2016-03-11",[384],[2496],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"intervention":665,"totalTrials":129,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2527,"PHASE4":2533,"NA":2535},{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[2529],{"nctId":655,"briefTitle":656,"status":111,"phases":2530,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":2531,"interventions":2532},[90],[597,663],[600,665,666],{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":99},[],{"intervention":666,"totalTrials":129,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2543,"PHASE3":2545,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[2547],{"nctId":655,"briefTitle":656,"status":111,"phases":2548,"primaryCompletion":658,"completion":659,"start":660,"enrollment":661,"conditions":2549,"interventions":2550},[90],[597,663],[600,665,666],{"trials":2552,"activeCount":99},[],{"trials":2554,"activeCount":99},[],{"intervention":1546,"totalTrials":129,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2561,"PHASE3":2563,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":99},[],{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[2565],{"nctId":1540,"briefTitle":1541,"status":111,"phases":2566,"completion":821,"start":1543,"enrollment":674,"conditions":2567,"interventions":2568},[90],[15],[1529,1546],{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[],{"intervention":2574,"totalTrials":129,"cells":2575},"vitamin D",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2594,"NA":2596},{"trials":2577,"activeCount":99},[],{"trials":2579,"activeCount":99},[],{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[2584],{"nctId":2585,"briefTitle":2586,"status":457,"phases":2587,"primaryCompletion":2588,"completion":2128,"start":2589,"enrollment":2590,"conditions":2591,"interventions":2593},"NCT00548379","Kabul Vitamin D Supplementation Trial",[90],"2009-06","2007-11",3048,[384,2592],"Vitamin D Deficiency",[2574],{"trials":2595,"activeCount":99},[],{"trials":2597,"activeCount":99},[],{"intervention":1644,"totalTrials":129,"cells":2599},{"EARLY_PHASE1":2600,"PHASE1":2602,"PHASE2":2604,"PHASE3":2606,"PHASE4":2612,"NA":2614},{"trials":2601,"activeCount":99},[],{"trials":2603,"activeCount":99},[],{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[2608],{"nctId":1637,"briefTitle":1638,"status":111,"phases":2609,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":760,"conditions":2610,"interventions":2611},[89,90],[32],[1644,1616,1645],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"intervention":1645,"totalTrials":129,"cells":2617},{"EARLY_PHASE1":2618,"PHASE1":2620,"PHASE2":2622,"PHASE3":2624,"PHASE4":2630,"NA":2632},{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[],{"trials":2623,"activeCount":99},[],{"trials":2625,"activeCount":99},[2626],{"nctId":1637,"briefTitle":1638,"status":111,"phases":2627,"primaryCompletion":1640,"completion":1640,"start":1641,"enrollment":760,"conditions":2628,"interventions":2629},[89,90],[32],[1644,1616,1645],{"trials":2631,"activeCount":99},[],{"trials":2633,"activeCount":99},[],{"intervention":1597,"totalTrials":129,"cells":2635},{"EARLY_PHASE1":2636,"PHASE1":2638,"PHASE2":2640,"PHASE3":2642,"PHASE4":2648,"NA":2650},{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[2644],{"nctId":1588,"briefTitle":1589,"status":111,"phases":2645,"primaryCompletion":1591,"completion":1592,"start":1593,"enrollment":1594,"conditions":2646,"interventions":2647},[90],[15],[1556,1597,1598],{"trials":2649,"activeCount":99},[],{"trials":2651,"activeCount":99},[],{"intervention":2653,"totalTrials":129,"cells":2654},"Azithromycin and Placebo",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2674,"NA":2676},{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[2663],{"nctId":2664,"briefTitle":2665,"status":111,"phases":2666,"primaryCompletion":2667,"completion":2668,"start":2669,"enrollment":2670,"conditions":2671,"interventions":2673},"NCT01800942","Prevention of Bacterial Infections in Newborn",[90],"2014-12","2015-08","2013-02",829,[2672],"Neonatal Infection",[2653],{"trials":2675,"activeCount":99},[],{"trials":2677,"activeCount":99},[],{"intervention":1437,"totalTrials":129,"cells":2679},{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2684,"PHASE3":2686,"PHASE4":2692,"NA":2694},{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"trials":2685,"activeCount":99},[],{"trials":2687,"activeCount":99},[2688],{"nctId":1427,"briefTitle":1428,"status":111,"phases":2689,"primaryCompletion":1430,"completion":1431,"start":1432,"enrollment":1433,"conditions":2690,"interventions":2691},[90],[15,1435,347],[1437,1393],{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"intervention":678,"totalTrials":129,"cells":2697},{"EARLY_PHASE1":2698,"PHASE1":2700,"PHASE2":2702,"PHASE3":2704,"PHASE4":2710,"NA":2712},{"trials":2699,"activeCount":99},[],{"trials":2701,"activeCount":99},[],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[2706],{"nctId":668,"briefTitle":669,"status":457,"phases":2707,"primaryCompletion":671,"completion":672,"start":673,"enrollment":674,"conditions":2708,"interventions":2709},[90],[676],[600,678],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"intervention":1523,"totalTrials":129,"cells":2715},{"EARLY_PHASE1":2716,"PHASE1":2718,"PHASE2":2720,"PHASE3":2722,"PHASE4":2728,"NA":2730},{"trials":2717,"activeCount":99},[],{"trials":2719,"activeCount":99},[],{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[2724],{"nctId":1516,"briefTitle":1517,"status":111,"phases":2725,"primaryCompletion":1519,"completion":1519,"start":700,"enrollment":1520,"conditions":2726,"interventions":2727},[90],[15],[1523,1486],{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"intervention":2733,"totalTrials":129,"cells":2734},"Artemether-Lumefantrine (AL) + 0.25 mg\u002Fkg primaquine",{"EARLY_PHASE1":2735,"PHASE1":2737,"PHASE2":2739,"PHASE3":2741,"PHASE4":2752,"NA":2754},{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[],{"trials":2742,"activeCount":99},[2743],{"nctId":2744,"briefTitle":2745,"status":111,"phases":2746,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":2747,"conditions":2748,"interventions":2749},"NCT02174900","Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)",[89,90],70,[15],[2733,2750,2751],"Artemether-Lumefantrine (AL) combination","Artemether-Lumefantrine (AL) + 0.4 mg\u002Fkg primaquine",{"trials":2753,"activeCount":99},[],{"trials":2755,"activeCount":99},[],{"intervention":2750,"totalTrials":129,"cells":2757},{"EARLY_PHASE1":2758,"PHASE1":2760,"PHASE2":2762,"PHASE3":2764,"PHASE4":2770,"NA":2772},{"trials":2759,"activeCount":99},[],{"trials":2761,"activeCount":99},[],{"trials":2763,"activeCount":99},[],{"trials":2765,"activeCount":99},[2766],{"nctId":2744,"briefTitle":2745,"status":111,"phases":2767,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":2747,"conditions":2768,"interventions":2769},[89,90],[15],[2733,2750,2751],{"trials":2771,"activeCount":99},[],{"trials":2773,"activeCount":99},[],{"intervention":2751,"totalTrials":129,"cells":2775},{"EARLY_PHASE1":2776,"PHASE1":2778,"PHASE2":2780,"PHASE3":2782,"PHASE4":2788,"NA":2790},{"trials":2777,"activeCount":99},[],{"trials":2779,"activeCount":99},[],{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[2784],{"nctId":2744,"briefTitle":2745,"status":111,"phases":2785,"primaryCompletion":1431,"completion":1431,"start":1432,"enrollment":2747,"conditions":2786,"interventions":2787},[89,90],[15],[2733,2750,2751],{"trials":2789,"activeCount":99},[],{"trials":2791,"activeCount":99},[],{"intervention":1557,"totalTrials":129,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2806,"NA":2808},{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[2802],{"nctId":1548,"briefTitle":1549,"status":111,"phases":2803,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":2804,"interventions":2805},[90],[15],[1556,1557,1558,1559],{"trials":2807,"activeCount":99},[],{"trials":2809,"activeCount":99},[],{"intervention":1558,"totalTrials":129,"cells":2811},{"EARLY_PHASE1":2812,"PHASE1":2814,"PHASE2":2816,"PHASE3":2818,"PHASE4":2824,"NA":2826},{"trials":2813,"activeCount":99},[],{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[],{"trials":2819,"activeCount":99},[2820],{"nctId":1548,"briefTitle":1549,"status":111,"phases":2821,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":1553,"conditions":2822,"interventions":2823},[90],[15],[1556,1557,1558,1559],{"trials":2825,"activeCount":99},[],{"trials":2827,"activeCount":99},[],{"intervention":1821,"totalTrials":129,"cells":2829},{"EARLY_PHASE1":2830,"PHASE1":2832,"PHASE2":2834,"PHASE3":2836,"PHASE4":2842,"NA":2844},{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"trials":2837,"activeCount":99},[2838],{"nctId":1813,"briefTitle":1814,"status":111,"phases":2839,"primaryCompletion":1816,"completion":785,"start":1817,"enrollment":1818,"conditions":2840,"interventions":2841},[89,90],[15],[1821,1822,1823],{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[],{"intervention":1823,"totalTrials":129,"cells":2847},{"EARLY_PHASE1":2848,"PHASE1":2850,"PHASE2":2852,"PHASE3":2854,"PHASE4":2860,"NA":2862},{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[],{"trials":2855,"activeCount":99},[2856],{"nctId":1813,"briefTitle":1814,"status":111,"phases":2857,"primaryCompletion":1816,"completion":785,"start":1817,"enrollment":1818,"conditions":2858,"interventions":2859},[89,90],[15],[1821,1822,1823],{"trials":2861,"activeCount":99},[],{"trials":2863,"activeCount":99},[],{"intervention":2865,"totalTrials":129,"cells":2866},"primaquine (PQ) plus SP+AS",{"EARLY_PHASE1":2867,"PHASE1":2869,"PHASE2":2871,"PHASE3":2873,"PHASE4":2884,"NA":2886},{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[],{"trials":2874,"activeCount":99},[2875],{"nctId":2876,"briefTitle":2877,"status":111,"phases":2878,"completion":2879,"start":1552,"enrollment":2880,"conditions":2881,"interventions":2883},"NCT00330902","Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan",[90],"2004-11",104,[2882],"Plasmodium Infections",[2419,2865],{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"intervention":2889,"totalTrials":129,"cells":2890},"meningococcal serogroup A conjugate vaccine",{"EARLY_PHASE1":2891,"PHASE1":2893,"PHASE2":2895,"PHASE3":2897,"PHASE4":2907,"NA":2909},{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[],{"trials":2898,"activeCount":99},[2899],{"nctId":2900,"briefTitle":2901,"status":457,"phases":2902,"primaryCompletion":2903,"completion":2245,"start":606,"enrollment":1240,"conditions":2904,"interventions":2906},"NCT03746665","Maternal Immunization With MenAfriVac™",[90],"2020-10-12",[1388,2905],"Meningococcal",[2889],{"trials":2908,"activeCount":99},[],{"trials":2910,"activeCount":99},[],{"intervention":729,"totalTrials":129,"cells":2912},{"EARLY_PHASE1":2913,"PHASE1":2915,"PHASE2":2917,"PHASE3":2919,"PHASE4":2925,"NA":2927},{"trials":2914,"activeCount":99},[],{"trials":2916,"activeCount":99},[],{"trials":2918,"activeCount":99},[],{"trials":2920,"activeCount":99},[2921],{"nctId":721,"briefTitle":722,"status":111,"phases":2922,"completion":724,"start":725,"enrollment":726,"conditions":2923,"interventions":2924},[90],[15],[729,730,688],{"trials":2926,"activeCount":99},[],{"trials":2928,"activeCount":99},[],{"intervention":730,"totalTrials":129,"cells":2930},{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2937,"PHASE4":2943,"NA":2945},{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[2939],{"nctId":721,"briefTitle":722,"status":111,"phases":2940,"completion":724,"start":725,"enrollment":726,"conditions":2941,"interventions":2942},[90],[15],[729,730,688],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"intervention":2948,"totalTrials":129,"cells":2949},"DHA-PQ",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2954,"PHASE3":2956,"PHASE4":2967,"NA":2969},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[2958],{"nctId":2959,"briefTitle":2960,"status":111,"phases":2961,"primaryCompletion":2962,"completion":2962,"start":2128,"enrollment":2963,"conditions":2964,"interventions":2965},"NCT00941785","Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso",[89,90],"2009-12",1500,[15],[2948,2966],"SP-AQ",{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[],{"intervention":2966,"totalTrials":129,"cells":2972},{"EARLY_PHASE1":2973,"PHASE1":2975,"PHASE2":2977,"PHASE3":2979,"PHASE4":2985,"NA":2987},{"trials":2974,"activeCount":99},[],{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[2981],{"nctId":2959,"briefTitle":2960,"status":111,"phases":2982,"primaryCompletion":2962,"completion":2962,"start":2128,"enrollment":2963,"conditions":2983,"interventions":2984},[89,90],[15],[2948,2966],{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[],{"intervention":2990,"totalTrials":129,"cells":2991},"SP plus amodiaquine",{"EARLY_PHASE1":2992,"PHASE1":2994,"PHASE2":2996,"PHASE3":2998,"PHASE4":3009,"NA":3011},{"trials":2993,"activeCount":99},[],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[],{"trials":2999,"activeCount":99},[3000],{"nctId":3001,"briefTitle":3002,"status":111,"phases":3003,"primaryCompletion":2128,"completion":3004,"start":738,"enrollment":3005,"conditions":3006,"interventions":3007},"NCT00944840","Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia",[90],"2009-08",1312,[15],[2990,3008],"SP placebo plus amodiaquine placebo",{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"intervention":3008,"totalTrials":129,"cells":3014},{"EARLY_PHASE1":3015,"PHASE1":3017,"PHASE2":3019,"PHASE3":3021,"PHASE4":3027,"NA":3029},{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"trials":3020,"activeCount":99},[],{"trials":3022,"activeCount":99},[3023],{"nctId":3001,"briefTitle":3002,"status":111,"phases":3024,"primaryCompletion":2128,"completion":3004,"start":738,"enrollment":3005,"conditions":3025,"interventions":3026},[90],[15],[2990,3008],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"intervention":3032,"totalTrials":129,"cells":3033},"Intermittent preventive treatment:sulphadoxine-pyrimethamine",{"EARLY_PHASE1":3034,"PHASE1":3036,"PHASE2":3038,"PHASE3":3040,"PHASE4":3050,"NA":3052},{"trials":3035,"activeCount":99},[],{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[3042],{"nctId":3043,"briefTitle":3044,"status":111,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":1552,"enrollment":3047,"conditions":3048,"interventions":3049},"NCT00142207","Preventing Malaria During Pregnancy in Epidemic-prone Areas.",[90],"2007-01",4775,[800],[3032],{"trials":3051,"activeCount":99},[],{"trials":3053,"activeCount":99},[],{"intervention":3055,"totalTrials":129,"cells":3056},"Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin",{"EARLY_PHASE1":3057,"PHASE1":3059,"PHASE2":3061,"PHASE3":3063,"PHASE4":3075,"NA":3077},{"trials":3058,"activeCount":99},[],{"trials":3060,"activeCount":99},[],{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[3065],{"nctId":3066,"briefTitle":3067,"status":111,"phases":3068,"primaryCompletion":658,"completion":658,"start":3069,"enrollment":3070,"conditions":3071,"interventions":3073},"NCT02211729","A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children",[90],"2014-05",22090,[15,3072],"Respiratory Infections",[3055,3074],"Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin",{"trials":3076,"activeCount":99},[],{"trials":3078,"activeCount":99},[],{"intervention":3074,"totalTrials":129,"cells":3080},{"EARLY_PHASE1":3081,"PHASE1":3083,"PHASE2":3085,"PHASE3":3087,"PHASE4":3093,"NA":3095},{"trials":3082,"activeCount":99},[],{"trials":3084,"activeCount":99},[],{"trials":3086,"activeCount":99},[],{"trials":3088,"activeCount":99},[3089],{"nctId":3066,"briefTitle":3067,"status":111,"phases":3090,"primaryCompletion":658,"completion":658,"start":3069,"enrollment":3070,"conditions":3091,"interventions":3092},[90],[15,3072],[3055,3074],{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"intervention":3098,"totalTrials":129,"cells":3099},"Sulphadoxine-pyrimethamine, amodiaquine",{"EARLY_PHASE1":3100,"PHASE1":3102,"PHASE2":3104,"PHASE3":3106,"PHASE4":3116,"NA":3118},{"trials":3101,"activeCount":99},[],{"trials":3103,"activeCount":99},[],{"trials":3105,"activeCount":99},[],{"trials":3107,"activeCount":99},[3108],{"nctId":3109,"briefTitle":3110,"status":111,"phases":3111,"completion":1360,"start":1783,"enrollment":3112,"conditions":3113,"interventions":3114},"NCT00146783","Navrongo Drug Options for IPT in Pregnancy Trial",[89,90],3642,[15],[3115,3098],"Sulphadoxine-pyrimethamine",{"trials":3117,"activeCount":99},[],{"trials":3119,"activeCount":99},[],{"intervention":3121,"totalTrials":129,"cells":3122},"sulfalene-pyrimethamine plus amodiaquine",{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3127,"PHASE3":3129,"PHASE4":3141,"NA":3143},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[],{"trials":3128,"activeCount":99},[],{"trials":3130,"activeCount":99},[3131],{"nctId":3132,"briefTitle":3133,"status":111,"phases":3134,"primaryCompletion":3135,"completion":3135,"start":1551,"enrollment":3136,"conditions":3137,"interventions":3138},"NCT00529620","Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal",[90],"2007-12",1833,[15],[3121,3139,3140],"dihydroartemisinin plus piperaquine","sulfadoxine pyrimethamine plus piperaquine",{"trials":3142,"activeCount":99},[],{"trials":3144,"activeCount":99},[],{"intervention":3139,"totalTrials":129,"cells":3146},{"EARLY_PHASE1":3147,"PHASE1":3149,"PHASE2":3151,"PHASE3":3153,"PHASE4":3159,"NA":3161},{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"trials":3152,"activeCount":99},[],{"trials":3154,"activeCount":99},[3155],{"nctId":3132,"briefTitle":3133,"status":111,"phases":3156,"primaryCompletion":3135,"completion":3135,"start":1551,"enrollment":3136,"conditions":3157,"interventions":3158},[90],[15],[3121,3139,3140],{"trials":3160,"activeCount":99},[],{"trials":3162,"activeCount":99},[],{"intervention":3140,"totalTrials":129,"cells":3164},{"EARLY_PHASE1":3165,"PHASE1":3167,"PHASE2":3169,"PHASE3":3171,"PHASE4":3177,"NA":3179},{"trials":3166,"activeCount":99},[],{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[3173],{"nctId":3132,"briefTitle":3133,"status":111,"phases":3174,"primaryCompletion":3135,"completion":3135,"start":1551,"enrollment":3136,"conditions":3175,"interventions":3176},[90],[15],[3121,3139,3140],{"trials":3178,"activeCount":99},[],{"trials":3180,"activeCount":99},[],{"intervention":1715,"totalTrials":129,"cells":3182},{"EARLY_PHASE1":3183,"PHASE1":3185,"PHASE2":3187,"PHASE3":3189,"PHASE4":3195,"NA":3197},{"trials":3184,"activeCount":99},[],{"trials":3186,"activeCount":99},[],{"trials":3188,"activeCount":99},[],{"trials":3190,"activeCount":99},[3191],{"nctId":1706,"briefTitle":1707,"status":111,"phases":3192,"primaryCompletion":1709,"completion":1709,"start":1710,"enrollment":1711,"conditions":3193,"interventions":3194},[90],[32,1713],[1715,1703,1682,1704],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[],{"intervention":3200,"totalTrials":129,"cells":3201},"sulphadoxine\u002Fpyrimethamine",{"EARLY_PHASE1":3202,"PHASE1":3204,"PHASE2":3206,"PHASE3":3208,"PHASE4":3220,"NA":3222},{"trials":3203,"activeCount":99},[],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[3210],{"nctId":3211,"briefTitle":3212,"status":1908,"phases":3213,"primaryCompletion":1817,"completion":3214,"start":2129,"enrollment":3215,"conditions":3216,"interventions":3217},"NCT00361114","IPT and Efficacy of Sulphadoxine\u002FPyrimethamine and Chlorproguanil\u002FDapsone in 6-59 Month Old Children With Malaria.",[90],"2007-10",112,[15],[3200,3218,3219],"Chlorproguanil\u002Fdapsone","Sulfadoxine\u002Fpyrimethamine",{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[],{"intervention":3218,"totalTrials":129,"cells":3225},{"EARLY_PHASE1":3226,"PHASE1":3228,"PHASE2":3230,"PHASE3":3232,"PHASE4":3238,"NA":3240},{"trials":3227,"activeCount":99},[],{"trials":3229,"activeCount":99},[],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[3234],{"nctId":3211,"briefTitle":3212,"status":1908,"phases":3235,"primaryCompletion":1817,"completion":3214,"start":2129,"enrollment":3215,"conditions":3236,"interventions":3237},[90],[15],[3200,3218,3219],{"trials":3239,"activeCount":99},[],{"trials":3241,"activeCount":99},[],{"intervention":3219,"totalTrials":129,"cells":3243},{"EARLY_PHASE1":3244,"PHASE1":3246,"PHASE2":3248,"PHASE3":3250,"PHASE4":3256,"NA":3258},{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[3252],{"nctId":3211,"briefTitle":3212,"status":1908,"phases":3253,"primaryCompletion":1817,"completion":3214,"start":2129,"enrollment":3215,"conditions":3254,"interventions":3255},[90],[15],[3200,3218,3219],{"trials":3257,"activeCount":99},[],{"trials":3259,"activeCount":99},[],{"intervention":3261,"totalTrials":129,"cells":3262},"Amodiaquine and Sulphadoxine\u002FPyrimethamine",{"EARLY_PHASE1":3263,"PHASE1":3265,"PHASE2":3267,"PHASE3":3269,"PHASE4":3278,"NA":3280},{"trials":3264,"activeCount":99},[],{"trials":3266,"activeCount":99},[],{"trials":3268,"activeCount":99},[],{"trials":3270,"activeCount":99},[3271],{"nctId":3272,"briefTitle":3273,"status":111,"phases":3274,"completion":224,"start":725,"enrollment":3275,"conditions":3276,"interventions":3277},"NCT00146718","Anti-Malarial Drug Resistance in Cameroon",[89,90],755,[15],[3261],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[],{"intervention":1787,"totalTrials":129,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3290,"PHASE4":3296,"NA":3298},{"trials":3285,"activeCount":99},[],{"trials":3287,"activeCount":99},[],{"trials":3289,"activeCount":99},[],{"trials":3291,"activeCount":99},[3292],{"nctId":1779,"briefTitle":1780,"status":111,"phases":3293,"completion":1782,"start":1783,"enrollment":1784,"conditions":3294,"interventions":3295},[90],[15],[1787,472,1788],{"trials":3297,"activeCount":99},[],{"trials":3299,"activeCount":99},[],{"intervention":3301,"totalTrials":129,"cells":3302},"9-valent human papillomavirus vaccine (Gardasil 9) - 3 doses",{"EARLY_PHASE1":3303,"PHASE1":3305,"PHASE2":3307,"PHASE3":3309,"PHASE4":3323,"NA":3325},{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":99},[],{"trials":3308,"activeCount":99},[],{"trials":3310,"activeCount":99},[3311],{"nctId":3312,"briefTitle":3313,"status":457,"phases":3314,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":3317,"conditions":3318,"interventions":3320},"NCT03832049","HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial",[90],"2024-06","2019-09-14",1720,[3319],"Human Papillomavirus Vaccine",[3301,3321,3322],"9-valent human papillomavirus vaccine (Gardasil 9) - 2 doses","9-valent human papillomavirus vaccine (Gardasil 9) - 1 dose",{"trials":3324,"activeCount":99},[],{"trials":3326,"activeCount":99},[],{"intervention":3321,"totalTrials":129,"cells":3328},{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3335,"PHASE4":3341,"NA":3343},{"trials":3330,"activeCount":99},[],{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[3337],{"nctId":3312,"briefTitle":3313,"status":457,"phases":3338,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":3317,"conditions":3339,"interventions":3340},[90],[3319],[3301,3321,3322],{"trials":3342,"activeCount":99},[],{"trials":3344,"activeCount":99},[],{"intervention":3322,"totalTrials":129,"cells":3346},{"EARLY_PHASE1":3347,"PHASE1":3349,"PHASE2":3351,"PHASE3":3353,"PHASE4":3359,"NA":3361},{"trials":3348,"activeCount":99},[],{"trials":3350,"activeCount":99},[],{"trials":3352,"activeCount":99},[],{"trials":3354,"activeCount":99},[3355],{"nctId":3312,"briefTitle":3313,"status":457,"phases":3356,"primaryCompletion":3315,"completion":3315,"start":3316,"enrollment":3317,"conditions":3357,"interventions":3358},[90],[3319],[3301,3321,3322],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"intervention":1570,"totalTrials":129,"cells":3364},{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3371,"PHASE4":3377,"NA":3379},{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[3373],{"nctId":1561,"briefTitle":1562,"status":111,"phases":3374,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":3375,"interventions":3376},[89,90],[15],[825,1569,1529,1570,1571,1572],{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[],{"intervention":1571,"totalTrials":129,"cells":3382},{"EARLY_PHASE1":3383,"PHASE1":3385,"PHASE2":3387,"PHASE3":3389,"PHASE4":3395,"NA":3397},{"trials":3384,"activeCount":99},[],{"trials":3386,"activeCount":99},[],{"trials":3388,"activeCount":99},[],{"trials":3390,"activeCount":99},[3391],{"nctId":1561,"briefTitle":1562,"status":111,"phases":3392,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":3393,"interventions":3394},[89,90],[15],[825,1569,1529,1570,1571,1572],{"trials":3396,"activeCount":99},[],{"trials":3398,"activeCount":99},[],{"intervention":1572,"totalTrials":129,"cells":3400},{"EARLY_PHASE1":3401,"PHASE1":3403,"PHASE2":3405,"PHASE3":3407,"PHASE4":3413,"NA":3415},{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[],{"trials":3406,"activeCount":99},[],{"trials":3408,"activeCount":99},[3409],{"nctId":1561,"briefTitle":1562,"status":111,"phases":3410,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":3411,"interventions":3412},[89,90],[15],[825,1569,1529,1570,1571,1572],{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[],{"intervention":764,"totalTrials":95,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3433,"PHASE4":3435,"NA":3437},{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[3425,3429],{"nctId":754,"briefTitle":755,"status":111,"phases":3426,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":3427,"interventions":3428},[89],[32],[763,764,745,472],{"nctId":766,"briefTitle":767,"status":111,"phases":3430,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":3431,"interventions":3432},[89],[32],[745,764,775,776],{"trials":3434,"activeCount":99},[],{"trials":3436,"activeCount":99},[],{"trials":3438,"activeCount":99},[],{"intervention":1633,"totalTrials":129,"cells":3440},{"EARLY_PHASE1":3441,"PHASE1":3443,"PHASE2":3445,"PHASE3":3451,"PHASE4":3453,"NA":3455},{"trials":3442,"activeCount":99},[],{"trials":3444,"activeCount":99},[],{"trials":3446,"activeCount":99},[3447],{"nctId":1625,"briefTitle":1626,"status":111,"phases":3448,"primaryCompletion":1628,"completion":1629,"start":1630,"enrollment":772,"conditions":3449,"interventions":3450},[89],[800],[1616,1633],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[],{"trials":3456,"activeCount":99},[],{"intervention":706,"totalTrials":129,"cells":3458},{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3469,"PHASE4":3471,"NA":3473},{"trials":3460,"activeCount":99},[],{"trials":3462,"activeCount":99},[],{"trials":3464,"activeCount":99},[3465],{"nctId":697,"briefTitle":698,"status":111,"phases":3466,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":3467,"interventions":3468},[88,89],[15,704],[706,707,688],{"trials":3470,"activeCount":99},[],{"trials":3472,"activeCount":99},[],{"trials":3474,"activeCount":99},[],{"intervention":707,"totalTrials":129,"cells":3476},{"EARLY_PHASE1":3477,"PHASE1":3479,"PHASE2":3481,"PHASE3":3487,"PHASE4":3489,"NA":3491},{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[3483],{"nctId":697,"briefTitle":698,"status":111,"phases":3484,"primaryCompletion":700,"completion":700,"start":701,"enrollment":702,"conditions":3485,"interventions":3486},[88,89],[15,704],[706,707,688],{"trials":3488,"activeCount":99},[],{"trials":3490,"activeCount":99},[],{"trials":3492,"activeCount":99},[],{"intervention":3494,"totalTrials":129,"cells":3495},"Ad26.ZEBOV, MVA-BN-Filo",{"EARLY_PHASE1":3496,"PHASE1":3498,"PHASE2":3500,"PHASE3":3523,"PHASE4":3525,"NA":3527},{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[3502],{"nctId":3503,"briefTitle":3504,"status":111,"phases":3505,"primaryCompletion":3506,"completion":3507,"start":3508,"enrollment":3509,"conditions":3510,"interventions":3522},"NCT05284097","Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study",[89],"2023-03-02","2024-10-31","2022-09-19",133,[3511,3512,3513,3514,3515,3516,3517,3518,3519,3520,3521],"Virus Diseases","Hemorrhagic Fever, Ebola","Infections","Hemorrhagic Fevers, Viral","RNA Virus Infections","Filoviridae Infections","Mononegavirales Infections","Vaccines","Immunologic Factors","Physiological Effects of Drugs","Ebola",[3494],{"trials":3524,"activeCount":99},[],{"trials":3526,"activeCount":99},[],{"trials":3528,"activeCount":99},[],{"intervention":3530,"totalTrials":129,"cells":3531},"Tranexamic Acid 100Mg\u002FMl Inj Vil 10Ml",{"EARLY_PHASE1":3532,"PHASE1":3534,"PHASE2":3536,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3533,"activeCount":99},[],{"trials":3535,"activeCount":99},[],{"trials":3537,"activeCount":99},[3538],{"nctId":3539,"briefTitle":3540,"status":111,"phases":3541,"primaryCompletion":3542,"completion":3543,"start":3544,"enrollment":1433,"conditions":3545,"interventions":3547},"NCT04274335","Pharmacokinetics and Pharmacodynamics of Tranexamic Acid in Women Having Caesarean Section Birth [WOMAN-PharmacoTXA]",[89],"2021-06-30","2021-09-30","2020-12-18",[3546],"Pregnancy, High Risk",[3530,3548,3549],"Tranexamic Acid Oral Solution","Tranexamic Acid Injectable Product",{"trials":3551,"activeCount":99},[],{"trials":3553,"activeCount":99},[],{"trials":3555,"activeCount":99},[],{"intervention":3548,"totalTrials":129,"cells":3557},{"EARLY_PHASE1":3558,"PHASE1":3560,"PHASE2":3562,"PHASE3":3568,"PHASE4":3570,"NA":3572},{"trials":3559,"activeCount":99},[],{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[3564],{"nctId":3539,"briefTitle":3540,"status":111,"phases":3565,"primaryCompletion":3542,"completion":3543,"start":3544,"enrollment":1433,"conditions":3566,"interventions":3567},[89],[3546],[3530,3548,3549],{"trials":3569,"activeCount":99},[],{"trials":3571,"activeCount":99},[],{"trials":3573,"activeCount":99},[],{"intervention":3549,"totalTrials":129,"cells":3575},{"EARLY_PHASE1":3576,"PHASE1":3578,"PHASE2":3580,"PHASE3":3586,"PHASE4":3588,"NA":3590},{"trials":3577,"activeCount":99},[],{"trials":3579,"activeCount":99},[],{"trials":3581,"activeCount":99},[3582],{"nctId":3539,"briefTitle":3540,"status":111,"phases":3583,"primaryCompletion":3542,"completion":3543,"start":3544,"enrollment":1433,"conditions":3584,"interventions":3585},[89],[3546],[3530,3548,3549],{"trials":3587,"activeCount":99},[],{"trials":3589,"activeCount":99},[],{"trials":3591,"activeCount":99},[],{"intervention":3593,"totalTrials":129,"cells":3594},"Sulfadoxine-pyrimethamine + artesunate",{"EARLY_PHASE1":3595,"PHASE1":3597,"PHASE2":3599,"PHASE3":3611,"PHASE4":3613,"NA":3615},{"trials":3596,"activeCount":99},[],{"trials":3598,"activeCount":99},[],{"trials":3600,"activeCount":99},[3601],{"nctId":3602,"briefTitle":3603,"status":111,"phases":3604,"completion":3605,"start":3606,"enrollment":3607,"conditions":3608,"interventions":3610},"NCT00486694","Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria",[89],"2004-08","2004-03",190,[3609],"Malaria, Vivax",[3593,1412],{"trials":3612,"activeCount":99},[],{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"intervention":3618,"totalTrials":129,"cells":3619},"Ad26.ZEBOV booster vaccination, given at a dose of 5x10^10 vp, via IM",{"EARLY_PHASE1":3620,"PHASE1":3622,"PHASE2":3624,"PHASE3":3635,"PHASE4":3637,"NA":3639},{"trials":3621,"activeCount":99},[],{"trials":3623,"activeCount":99},[],{"trials":3625,"activeCount":99},[3626],{"nctId":3627,"briefTitle":3628,"status":111,"phases":3629,"primaryCompletion":3630,"completion":1696,"start":3631,"enrollment":3632,"conditions":3633,"interventions":3634},"NCT04711356","Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)",[89],"2021-09-17","2021-07-08",50,[2037],[3618],{"trials":3636,"activeCount":99},[],{"trials":3638,"activeCount":99},[],{"trials":3640,"activeCount":99},[],{"intervention":3642,"totalTrials":129,"cells":3643},"Ad26.ZEBOV",{"EARLY_PHASE1":3644,"PHASE1":3646,"PHASE2":3648,"PHASE3":3661,"PHASE4":3663,"NA":3665},{"trials":3645,"activeCount":99},[],{"trials":3647,"activeCount":99},[],{"trials":3649,"activeCount":99},[3650],{"nctId":3651,"briefTitle":3652,"status":111,"phases":3653,"primaryCompletion":3654,"completion":3655,"start":3656,"enrollment":3657,"conditions":3658,"interventions":3660},"NCT05064956","Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV\u002FMVA-BN-Filo (EBOVAC HIV+ Booster Study)",[89],"2021-11-17","2022-10-24","2021-10-06",26,[2037,3521,3659],"Hiv",[3642],{"trials":3662,"activeCount":99},[],{"trials":3664,"activeCount":99},[],{"trials":3666,"activeCount":99},[],{"intervention":3668,"totalTrials":129,"cells":3669},"Tranexamic 1 gram",{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3674,"PHASE3":3686,"PHASE4":3688,"NA":3690},{"trials":3671,"activeCount":99},[],{"trials":3673,"activeCount":99},[],{"trials":3675,"activeCount":99},[3676],{"nctId":3677,"briefTitle":3678,"status":111,"phases":3679,"primaryCompletion":3680,"completion":3680,"start":3681,"enrollment":3682,"conditions":3683,"interventions":3685},"NCT03875937","The Trauma INtramuscular Tranexamic Acid Clinical Trial",[88,89],"2020-02-12","2019-09-17",31,[3684],"Traumatic Haemorrhage",[3668],{"trials":3687,"activeCount":99},[],{"trials":3689,"activeCount":99},[],{"trials":3691,"activeCount":99},[],{"intervention":1501,"totalTrials":129,"cells":3693},{"EARLY_PHASE1":3694,"PHASE1":3696,"PHASE2":3698,"PHASE3":3704,"PHASE4":3706,"NA":3708},{"trials":3695,"activeCount":99},[],{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[3700],{"nctId":1495,"briefTitle":1496,"status":111,"phases":3701,"primaryCompletion":700,"completion":700,"start":1498,"enrollment":1433,"conditions":3702,"interventions":3703},[88,89],[15],[1486,1501,1502],{"trials":3705,"activeCount":99},[],{"trials":3707,"activeCount":99},[],{"trials":3709,"activeCount":99},[],{"intervention":1502,"totalTrials":129,"cells":3711},{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3716,"PHASE3":3722,"PHASE4":3724,"NA":3726},{"trials":3713,"activeCount":99},[],{"trials":3715,"activeCount":99},[],{"trials":3717,"activeCount":99},[3718],{"nctId":1495,"briefTitle":1496,"status":111,"phases":3719,"primaryCompletion":700,"completion":700,"start":1498,"enrollment":1433,"conditions":3720,"interventions":3721},[88,89],[15],[1486,1501,1502],{"trials":3723,"activeCount":99},[],{"trials":3725,"activeCount":99},[],{"trials":3727,"activeCount":99},[],{"intervention":3729,"totalTrials":129,"cells":3730},"FP9 ME-TRAP",{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3744,"PHASE4":3746,"NA":3748},{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[],{"trials":3736,"activeCount":99},[3737],{"nctId":3738,"briefTitle":3739,"status":111,"phases":3740,"completion":1782,"start":1783,"enrollment":1433,"conditions":3741,"interventions":3742},"NCT00121823","Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines",[88,89],[15],[3729,3743],"MVA ME-TRAP",{"trials":3745,"activeCount":99},[],{"trials":3747,"activeCount":99},[],{"trials":3749,"activeCount":99},[],{"intervention":3743,"totalTrials":129,"cells":3751},{"EARLY_PHASE1":3752,"PHASE1":3754,"PHASE2":3756,"PHASE3":3762,"PHASE4":3764,"NA":3766},{"trials":3753,"activeCount":99},[],{"trials":3755,"activeCount":99},[],{"trials":3757,"activeCount":99},[3758],{"nctId":3738,"briefTitle":3739,"status":111,"phases":3759,"completion":1782,"start":1783,"enrollment":1433,"conditions":3760,"interventions":3761},[88,89],[15],[3729,3743],{"trials":3763,"activeCount":99},[],{"trials":3765,"activeCount":99},[],{"trials":3767,"activeCount":99},[],{"intervention":763,"totalTrials":129,"cells":3769},{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3780,"PHASE4":3782,"NA":3784},{"trials":3771,"activeCount":99},[],{"trials":3773,"activeCount":99},[],{"trials":3775,"activeCount":99},[3776],{"nctId":754,"briefTitle":755,"status":111,"phases":3777,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":3778,"interventions":3779},[89],[32],[763,764,745,472],{"trials":3781,"activeCount":99},[],{"trials":3783,"activeCount":99},[],{"trials":3785,"activeCount":99},[],{"intervention":775,"totalTrials":129,"cells":3787},{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3798,"PHASE4":3800,"NA":3802},{"trials":3789,"activeCount":99},[],{"trials":3791,"activeCount":99},[],{"trials":3793,"activeCount":99},[3794],{"nctId":766,"briefTitle":767,"status":111,"phases":3795,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":3796,"interventions":3797},[89],[32],[745,764,775,776],{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[],{"trials":3803,"activeCount":99},[],{"intervention":776,"totalTrials":129,"cells":3805},{"EARLY_PHASE1":3806,"PHASE1":3808,"PHASE2":3810,"PHASE3":3816,"PHASE4":3818,"NA":3820},{"trials":3807,"activeCount":99},[],{"trials":3809,"activeCount":99},[],{"trials":3811,"activeCount":99},[3812],{"nctId":766,"briefTitle":767,"status":111,"phases":3813,"primaryCompletion":769,"completion":770,"start":771,"enrollment":772,"conditions":3814,"interventions":3815},[89],[32],[745,764,775,776],{"trials":3817,"activeCount":99},[],{"trials":3819,"activeCount":99},[],{"trials":3821,"activeCount":99},[],{"intervention":3823,"totalTrials":129,"cells":3824},"Tranexamic Acid 1 gram intravenously",{"EARLY_PHASE1":3825,"PHASE1":3827,"PHASE2":3841,"PHASE3":3843,"PHASE4":3845,"NA":3847},{"trials":3826,"activeCount":99},[],{"trials":3828,"activeCount":99},[3829],{"nctId":3830,"briefTitle":3831,"status":111,"phases":3832,"primaryCompletion":3833,"completion":3833,"start":3834,"enrollment":3835,"conditions":3836,"interventions":3838},"NCT03777488","Pharmacokinetics of Tranexamic Acid After Oral, Intramuscular or Intravenous Administration: a Prospective, Randomised, Cross-over Trial in Healthy Volunteers.",[88],"2020-10-14","2019-10-30",15,[3837],"Healthy Volunteer Study",[3823,3839,3840],"Tranexamic acid 2 grams oral solution","Tranexamic acid 1 gram intramuscular",{"trials":3842,"activeCount":99},[],{"trials":3844,"activeCount":99},[],{"trials":3846,"activeCount":99},[],{"trials":3848,"activeCount":99},[],{"intervention":3839,"totalTrials":129,"cells":3850},{"EARLY_PHASE1":3851,"PHASE1":3853,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3852,"activeCount":99},[],{"trials":3854,"activeCount":99},[3855],{"nctId":3830,"briefTitle":3831,"status":111,"phases":3856,"primaryCompletion":3833,"completion":3833,"start":3834,"enrollment":3835,"conditions":3857,"interventions":3858},[88],[3837],[3823,3839,3840],{"trials":3860,"activeCount":99},[],{"trials":3862,"activeCount":99},[],{"trials":3864,"activeCount":99},[],{"trials":3866,"activeCount":99},[],{"intervention":3840,"totalTrials":129,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3870,"activeCount":99},[],{"trials":3872,"activeCount":99},[3873],{"nctId":3830,"briefTitle":3831,"status":111,"phases":3874,"primaryCompletion":3833,"completion":3833,"start":3834,"enrollment":3835,"conditions":3875,"interventions":3876},[88],[3837],[3823,3839,3840],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"trials":3882,"activeCount":99},[],{"trials":3884,"activeCount":99},[],{"intervention":3886,"totalTrials":129,"cells":3887},"FP9 CS",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3901,"PHASE3":3903,"PHASE4":3905,"NA":3907},{"trials":3889,"activeCount":99},[],{"trials":3891,"activeCount":99},[3892],{"nctId":3893,"briefTitle":3894,"status":111,"phases":3895,"completion":3896,"start":1552,"enrollment":3897,"conditions":3898,"interventions":3899},"NCT00121771","Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men",[88],"2004-07",32,[15],[3886,3900],"MVA CS",{"trials":3902,"activeCount":99},[],{"trials":3904,"activeCount":99},[],{"trials":3906,"activeCount":99},[],{"trials":3908,"activeCount":99},[],{"intervention":3900,"totalTrials":129,"cells":3910},{"EARLY_PHASE1":3911,"PHASE1":3913,"PHASE2":3919,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[3915],{"nctId":3893,"briefTitle":3894,"status":111,"phases":3916,"completion":3896,"start":1552,"enrollment":3897,"conditions":3917,"interventions":3918},[88],[15],[3886,3900],{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[],{"trials":3924,"activeCount":99},[],{"trials":3926,"activeCount":99},[],{"intervention":1412,"totalTrials":28,"cells":3928},{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3943,"PHASE4":3963,"NA":3974},{"trials":3930,"activeCount":99},[],{"trials":3932,"activeCount":99},[],{"trials":3934,"activeCount":99},[3935,3939],{"nctId":3602,"briefTitle":3603,"status":111,"phases":3936,"completion":3605,"start":3606,"enrollment":3607,"conditions":3937,"interventions":3938},[89],[3609],[3593,1412],{"nctId":1402,"briefTitle":1403,"status":111,"phases":3940,"primaryCompletion":821,"completion":1405,"start":1406,"enrollment":1407,"conditions":3941,"interventions":3942},[89],[1409],[1411,825,1412,1413],{"trials":3944,"activeCount":99},[3945,3954],{"nctId":3946,"briefTitle":3947,"status":457,"phases":3948,"primaryCompletion":1910,"completion":3949,"start":3950,"enrollment":1433,"conditions":3951,"interventions":3953},"NCT01718054","Vascular Function Intervention Trial in Sickle Cell Disease",[89,90],"2017-09","2012-08",[3952],"Sickle Cell Disease",[1412],{"nctId":3955,"briefTitle":3956,"status":111,"phases":3957,"completion":3958,"start":3959,"enrollment":3960,"conditions":3961,"interventions":3962},"NCT00131703","Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women",[90],"2005-03","2003-03",900,[15,30],[472,3115,1412],{"trials":3964,"activeCount":99},[3965],{"nctId":3966,"briefTitle":3967,"status":111,"phases":3968,"primaryCompletion":3969,"completion":3969,"start":3970,"enrollment":3971,"conditions":3972,"interventions":3973},"NCT01019408","Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan",[91],"1995-01","1993-11",163,[800],[1412],{"trials":3975,"activeCount":99},[3976,3987,3995],{"nctId":3977,"briefTitle":3978,"status":111,"phases":3979,"completion":3980,"start":725,"enrollment":3981,"conditions":3982,"interventions":3984},"NCT00132535","Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda",[92],"2007-06",2548,[3983,27],"Malaria in Pregnancy",[3985,3986],"sulfadoxine-pyrimethamine intermittent preventive treatment","chloroquine",{"nctId":3988,"briefTitle":3989,"status":111,"phases":3990,"completion":3991,"start":2009,"enrollment":3992,"conditions":3993,"interventions":3994},"NCT00169078","Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance",[92],"2002-12",1035,[15],[1412],{"nctId":3996,"briefTitle":3997,"status":111,"phases":3998,"primaryCompletion":3980,"completion":3999,"start":4000,"enrollment":4001,"conditions":4002,"interventions":4004},"NCT00140517","Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance",[92],"2008-03","2002-10",700,[3983,4003,18],"Birth Weight",[825,3986],{"intervention":637,"totalTrials":35,"cells":4006},{"EARLY_PHASE1":4007,"PHASE1":4009,"PHASE2":4011,"PHASE3":4025,"PHASE4":4039,"NA":4053},{"trials":4008,"activeCount":99},[],{"trials":4010,"activeCount":99},[],{"trials":4012,"activeCount":99},[4013],{"nctId":4014,"briefTitle":4015,"status":111,"phases":4016,"primaryCompletion":4017,"completion":4018,"start":1910,"enrollment":4019,"conditions":4020,"interventions":4024},"NCT02909712","Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania",[89],"2020-01","2020-02",201,[15,2329,4021,4022,4023],"Cardiotoxicity","Cardiac Safety","Parasitemia",[2419,637],{"trials":4026,"activeCount":99},[4027,4031,4035],{"nctId":628,"briefTitle":629,"status":111,"phases":4028,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":4029,"interventions":4030},[90],[15],[637,638],{"nctId":640,"briefTitle":641,"status":457,"phases":4032,"primaryCompletion":643,"completion":644,"start":645,"enrollment":646,"conditions":4033,"interventions":4034},[90],[32,648,649,650,597,651,464],[600,653],{"nctId":2412,"briefTitle":2413,"status":111,"phases":4036,"primaryCompletion":785,"completion":785,"start":1816,"enrollment":2415,"conditions":4037,"interventions":4038},[90],[15,2417],[2419,2401,637],{"trials":4040,"activeCount":99},[4041,4049],{"nctId":4042,"briefTitle":4043,"status":111,"phases":4044,"primaryCompletion":1130,"completion":1130,"start":4045,"enrollment":4046,"conditions":4047,"interventions":4048},"NCT02009215","School-Based Treatment With ACT to Reduce Transmission",[91],"2014-02",10746,[15],[653],{"nctId":794,"briefTitle":795,"status":111,"phases":4050,"primaryCompletion":571,"completion":571,"start":797,"enrollment":798,"conditions":4051,"interventions":4052},[91],[800],[802,745],{"trials":4054,"activeCount":99},[4055],{"nctId":4056,"briefTitle":4057,"status":111,"phases":4058,"primaryCompletion":4059,"completion":4060,"start":4061,"enrollment":4062,"conditions":4063,"interventions":4064},"NCT02878200","RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission",[92],"2018-12-18","2020-07-16","2016-11-04",2236,[15],[637],{"intervention":2419,"totalTrials":35,"cells":4066},{"EARLY_PHASE1":4067,"PHASE1":4069,"PHASE2":4071,"PHASE3":4077,"PHASE4":4105,"NA":4107},{"trials":4068,"activeCount":99},[],{"trials":4070,"activeCount":99},[],{"trials":4072,"activeCount":99},[4073],{"nctId":4014,"briefTitle":4015,"status":111,"phases":4074,"primaryCompletion":4017,"completion":4018,"start":1910,"enrollment":4019,"conditions":4075,"interventions":4076},[89],[15,2329,4021,4022,4023],[2419,637],{"trials":4078,"activeCount":99},[4079,4086,4090,4094,4098],{"nctId":4080,"briefTitle":4081,"status":111,"phases":4082,"completion":224,"start":4083,"enrollment":674,"conditions":4084,"interventions":4085},"NCT00131716","Prevention of Severe Anaemia in Gambian Children",[90],"2003-05",[24],[2419],{"nctId":2412,"briefTitle":2413,"status":111,"phases":4087,"primaryCompletion":785,"completion":785,"start":1816,"enrollment":2415,"conditions":4088,"interventions":4089},[90],[15,2417],[2419,2401,637],{"nctId":2459,"briefTitle":2460,"status":111,"phases":4091,"completion":2462,"start":2463,"enrollment":1510,"conditions":4092,"interventions":4093},[90],[2465],[2467,2448],{"nctId":2876,"briefTitle":2877,"status":111,"phases":4095,"completion":2879,"start":1552,"enrollment":2880,"conditions":4096,"interventions":4097},[90],[2882],[2419,2865],{"nctId":4099,"briefTitle":4100,"status":111,"phases":4101,"completion":1543,"start":2009,"enrollment":4102,"conditions":4103,"interventions":4104},"NCT00120809","Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae",[90],3000,[15],[2467],{"trials":4106,"activeCount":99},[],{"trials":4108,"activeCount":99},[4109],{"nctId":4110,"briefTitle":4111,"status":111,"phases":4112,"completion":1783,"start":4113,"enrollment":4114,"conditions":4115,"interventions":4116},"NCT00857077","Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana",[92],"2000-09",2485,[18,15],[2467],{"intervention":825,"totalTrials":189,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4121,"PHASE2":4123,"PHASE3":4129,"PHASE4":4147,"NA":4149},{"trials":4120,"activeCount":99},[],{"trials":4122,"activeCount":99},[],{"trials":4124,"activeCount":99},[4125],{"nctId":1402,"briefTitle":1403,"status":111,"phases":4126,"primaryCompletion":821,"completion":1405,"start":1406,"enrollment":1407,"conditions":4127,"interventions":4128},[89],[1409],[1411,825,1412,1413],{"trials":4130,"activeCount":99},[4131,4135,4139,4143],{"nctId":3955,"briefTitle":3956,"status":111,"phases":4132,"completion":3958,"start":3959,"enrollment":3960,"conditions":4133,"interventions":4134},[90],[15,30],[472,3115,1412],{"nctId":817,"briefTitle":818,"status":111,"phases":4136,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":4137,"interventions":4138},[89,90],[15],[806,825],{"nctId":3109,"briefTitle":3110,"status":111,"phases":4140,"completion":1360,"start":1783,"enrollment":3112,"conditions":4141,"interventions":4142},[89,90],[15],[3115,3098],{"nctId":1561,"briefTitle":1562,"status":111,"phases":4144,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":4145,"interventions":4146},[89,90],[15],[825,1569,1529,1570,1571,1572],{"trials":4148,"activeCount":99},[],{"trials":4150,"activeCount":99},[4151],{"nctId":3996,"briefTitle":3997,"status":111,"phases":4152,"primaryCompletion":3980,"completion":3999,"start":4000,"enrollment":4001,"conditions":4153,"interventions":4154},[92],[3983,4003,18],[825,3986],{"intervention":472,"totalTrials":475,"cells":4156},{"EARLY_PHASE1":4157,"PHASE1":4159,"PHASE2":4161,"PHASE3":4167,"PHASE4":4177,"NA":4179},{"trials":4158,"activeCount":99},[],{"trials":4160,"activeCount":99},[],{"trials":4162,"activeCount":99},[4163],{"nctId":754,"briefTitle":755,"status":111,"phases":4164,"primaryCompletion":757,"completion":758,"start":759,"enrollment":760,"conditions":4165,"interventions":4166},[89],[32],[763,764,745,472],{"trials":4168,"activeCount":99},[4169,4173],{"nctId":3955,"briefTitle":3956,"status":111,"phases":4170,"completion":3958,"start":3959,"enrollment":3960,"conditions":4171,"interventions":4172},[90],[15,30],[472,3115,1412],{"nctId":1779,"briefTitle":1780,"status":111,"phases":4174,"completion":1782,"start":1783,"enrollment":1784,"conditions":4175,"interventions":4176},[90],[15],[1787,472,1788],{"trials":4178,"activeCount":99},[],{"trials":4180,"activeCount":99},[4181],{"nctId":455,"briefTitle":456,"status":457,"phases":4182,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":4183,"interventions":4184},[92],[15,464,465,466,467,468],[470,471,472,56],{"intervention":470,"totalTrials":428,"cells":4186},{"EARLY_PHASE1":4187,"PHASE1":4189,"PHASE2":4191,"PHASE3":4193,"PHASE4":4195,"NA":4211},{"trials":4188,"activeCount":99},[],{"trials":4190,"activeCount":99},[],{"trials":4192,"activeCount":99},[],{"trials":4194,"activeCount":99},[],{"trials":4196,"activeCount":99},[4197],{"nctId":4198,"briefTitle":4199,"status":111,"phases":4200,"primaryCompletion":4201,"completion":4202,"start":4203,"enrollment":4204,"conditions":4205,"interventions":4209},"NCT02397772","Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya",[91],"2017-06","2017-07","2015-03",21761,[4206,4207,4208],"Helminthiasis","Nematode Infection","Disease Transmission, Infectious",[4210],"albendazole",{"trials":4212,"activeCount":99},[4213,4223],{"nctId":4214,"briefTitle":4215,"status":111,"phases":4216,"primaryCompletion":797,"completion":797,"start":1498,"enrollment":4217,"conditions":4218,"interventions":4222},"NCT01658774","Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children",[92],2377,[4219,4220,4221,15],"Intestinal Helminthiasis","Ascariasis","Hookworm",[470],{"nctId":455,"briefTitle":456,"status":457,"phases":4224,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":4225,"interventions":4226},[92],[15,464,465,466,467,468],[470,471,472,56],{"intervention":1569,"totalTrials":95,"cells":4228},{"EARLY_PHASE1":4229,"PHASE1":4231,"PHASE2":4233,"PHASE3":4235,"PHASE4":4241,"NA":4243},{"trials":4230,"activeCount":99},[],{"trials":4232,"activeCount":99},[],{"trials":4234,"activeCount":99},[],{"trials":4236,"activeCount":99},[4237],{"nctId":1561,"briefTitle":1562,"status":111,"phases":4238,"primaryCompletion":1564,"completion":785,"start":1565,"enrollment":1566,"conditions":4239,"interventions":4240},[89,90],[15],[825,1569,1529,1570,1571,1572],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[4245],{"nctId":4246,"briefTitle":4247,"status":111,"phases":4248,"primaryCompletion":4249,"completion":2962,"start":3214,"enrollment":4250,"conditions":4251,"interventions":4252},"NCT00499876","The Effect of Malaria on Disease Progression of HIV\u002FAIDS",[92],"2008-10",197,[27,15],[1569],{"intervention":4254,"totalTrials":129,"cells":4255},"sulphadoxine-pyrimethamine intermittent preventive treatment",{"EARLY_PHASE1":4256,"PHASE1":4258,"PHASE2":4260,"PHASE3":4262,"PHASE4":4264,"NA":4266},{"trials":4257,"activeCount":99},[],{"trials":4259,"activeCount":99},[],{"trials":4261,"activeCount":99},[],{"trials":4263,"activeCount":99},[],{"trials":4265,"activeCount":99},[],{"trials":4267,"activeCount":99},[4268],{"nctId":4269,"briefTitle":4270,"status":111,"phases":4271,"completion":3980,"start":4083,"enrollment":4272,"conditions":4273,"interventions":4274},"NCT00118027","A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda",[92],2150,[15,30,24],[4254],{"intervention":3985,"totalTrials":129,"cells":4276},{"EARLY_PHASE1":4277,"PHASE1":4279,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4278,"activeCount":99},[],{"trials":4280,"activeCount":99},[],{"trials":4282,"activeCount":99},[],{"trials":4284,"activeCount":99},[],{"trials":4286,"activeCount":99},[],{"trials":4288,"activeCount":99},[4289],{"nctId":3977,"briefTitle":3978,"status":111,"phases":4290,"completion":3980,"start":725,"enrollment":3981,"conditions":4291,"interventions":4292},[92],[3983,27],[3985,3986],{"intervention":4294,"totalTrials":129,"cells":4295},"Routine deworming",{"EARLY_PHASE1":4296,"PHASE1":4298,"PHASE2":4300,"PHASE3":4302,"PHASE4":4304,"NA":4306},{"trials":4297,"activeCount":99},[],{"trials":4299,"activeCount":99},[],{"trials":4301,"activeCount":99},[],{"trials":4303,"activeCount":99},[],{"trials":4305,"activeCount":99},[],{"trials":4307,"activeCount":99},[4308],{"nctId":4309,"briefTitle":4310,"status":111,"phases":4311,"primaryCompletion":4312,"completion":4313,"start":4314,"enrollment":1784,"conditions":4315,"interventions":4321},"NCT05914363","Evaluating Impact of Improved Floors on Health",[92],"2024-08-31","2024-09-30","2023-04-12",[4316,4317,4318,4319,4320],"Diarrhoeal Disease","Hookworm Infection","Ascaris Lumbricoides Infection","Trichuris Infection","Tungiasis",[4294],{"intervention":4323,"totalTrials":129,"cells":4324},"Sulphadoxine-pyrimethamine and Amodiaquine",{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4329,"PHASE3":4331,"PHASE4":4333,"NA":4335},{"trials":4326,"activeCount":99},[],{"trials":4328,"activeCount":99},[],{"trials":4330,"activeCount":99},[],{"trials":4332,"activeCount":99},[],{"trials":4334,"activeCount":99},[],{"trials":4336,"activeCount":99},[4337],{"nctId":4338,"briefTitle":4339,"status":457,"phases":4340,"primaryCompletion":4341,"completion":4342,"start":4343,"enrollment":674,"conditions":4344,"interventions":4345},"NCT06182176","Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control",[92],"2024-11-29","2026-01-12","2024-05-27",[15,464,465,467,468],[4323],{"intervention":4347,"totalTrials":129,"cells":4348},"Intermittent preventive treatment with AQ+ SP",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4353,"PHASE3":4355,"PHASE4":4357,"NA":4359},{"trials":4350,"activeCount":99},[],{"trials":4352,"activeCount":99},[],{"trials":4354,"activeCount":99},[],{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[4361],{"nctId":4362,"briefTitle":4363,"status":111,"phases":4364,"primaryCompletion":783,"completion":2962,"start":4365,"enrollment":4366,"conditions":4367,"interventions":4368},"NCT00738946","A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children",[92],"2008-08",6000,[15],[4347],{"intervention":4370,"totalTrials":129,"cells":4371},"Chlorproguanil-dapsone + artesunate",{"EARLY_PHASE1":4372,"PHASE1":4374,"PHASE2":4376,"PHASE3":4378,"PHASE4":4380,"NA":4382},{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"trials":4377,"activeCount":99},[],{"trials":4379,"activeCount":99},[],{"trials":4381,"activeCount":99},[],{"trials":4383,"activeCount":99},[4384],{"nctId":4385,"briefTitle":4386,"status":111,"phases":4387,"completion":4388,"start":4389,"enrollment":4390,"conditions":4391,"interventions":4392},"NCT00461578","Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children",[92],"2006-10","2005-04",800,[15],[4370],{"intervention":4394,"totalTrials":129,"cells":4395},"Albendazole 400mg and ivermectin 200mcg\u002Fkg",{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4400,"PHASE3":4402,"PHASE4":4404,"NA":4406},{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[],{"trials":4401,"activeCount":99},[],{"trials":4403,"activeCount":99},[],{"trials":4405,"activeCount":99},[],{"trials":4407,"activeCount":99},[4408],{"nctId":4409,"briefTitle":4410,"status":1908,"phases":4411,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":2747,"conditions":4414,"interventions":4415},"NCT01213576","Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi",[92],"2012-02","2009-01",[650],[4394,4416,4394,4417],"Albendazole and ivermectin","albendazole 800mg and ivermectin 400mcg\u002Fkg bi-annually",{"intervention":4416,"totalTrials":129,"cells":4419},{"EARLY_PHASE1":4420,"PHASE1":4422,"PHASE2":4424,"PHASE3":4426,"PHASE4":4428,"NA":4430},{"trials":4421,"activeCount":99},[],{"trials":4423,"activeCount":99},[],{"trials":4425,"activeCount":99},[],{"trials":4427,"activeCount":99},[],{"trials":4429,"activeCount":99},[],{"trials":4431,"activeCount":99},[4432],{"nctId":4409,"briefTitle":4410,"status":1908,"phases":4433,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":2747,"conditions":4434,"interventions":4435},[92],[650],[4394,4416,4394,4417],{"intervention":4417,"totalTrials":129,"cells":4437},{"EARLY_PHASE1":4438,"PHASE1":4440,"PHASE2":4442,"PHASE3":4444,"PHASE4":4446,"NA":4448},{"trials":4439,"activeCount":99},[],{"trials":4441,"activeCount":99},[],{"trials":4443,"activeCount":99},[],{"trials":4445,"activeCount":99},[],{"trials":4447,"activeCount":99},[],{"trials":4449,"activeCount":99},[4450],{"nctId":4409,"briefTitle":4410,"status":1908,"phases":4451,"primaryCompletion":4412,"completion":4412,"start":4413,"enrollment":2747,"conditions":4452,"interventions":4453},[92],[650],[4394,4416,4394,4417],{"intervention":4455,"totalTrials":129,"cells":4456},"Artemether lumefantrine",{"EARLY_PHASE1":4457,"PHASE1":4459,"PHASE2":4461,"PHASE3":4463,"PHASE4":4465,"NA":4467},{"trials":4458,"activeCount":99},[],{"trials":4460,"activeCount":99},[],{"trials":4462,"activeCount":99},[],{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[],{"trials":4468,"activeCount":99},[4469],{"nctId":4470,"briefTitle":4471,"status":111,"phases":4472,"primaryCompletion":4203,"completion":4203,"start":4473,"enrollment":4474,"conditions":4475,"interventions":4476},"NCT02213211","School-based Programme of Malaria Diagnosis and Treatment in Southern Malawi",[92],"2014-04",3667,[15],[4455],{"intervention":4478,"totalTrials":129,"cells":4479},"Intermittent screening and treatment for malaria",{"EARLY_PHASE1":4480,"PHASE1":4482,"PHASE2":4484,"PHASE3":4486,"PHASE4":4488,"NA":4490},{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[],{"trials":4485,"activeCount":99},[],{"trials":4487,"activeCount":99},[],{"trials":4489,"activeCount":99},[],{"trials":4491,"activeCount":99},[4492],{"nctId":4493,"briefTitle":4494,"status":111,"phases":4495,"primaryCompletion":4496,"completion":4496,"start":4497,"enrollment":4498,"conditions":4499,"interventions":4500},"NCT00878007","Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren",[92],"2012-04","2010-01",5177,[18,15],[4478],{"intervention":471,"totalTrials":129,"cells":4502},{"EARLY_PHASE1":4503,"PHASE1":4505,"PHASE2":4507,"PHASE3":4509,"PHASE4":4511,"NA":4513},{"trials":4504,"activeCount":99},[],{"trials":4506,"activeCount":99},[],{"trials":4508,"activeCount":99},[],{"trials":4510,"activeCount":99},[],{"trials":4512,"activeCount":99},[],{"trials":4514,"activeCount":99},[4515],{"nctId":455,"briefTitle":456,"status":457,"phases":4516,"primaryCompletion":459,"completion":460,"start":461,"enrollment":462,"conditions":4517,"interventions":4518},[92],[15,464,465,466,467,468],[470,471,472,56],{"intervention":4520,"totalTrials":129,"cells":4521},"Intermittent parasite clearance",{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"trials":4529,"activeCount":99},[],{"trials":4531,"activeCount":99},[],{"trials":4533,"activeCount":99},[4534],{"nctId":4535,"briefTitle":4536,"status":111,"phases":4537,"primaryCompletion":4412,"completion":4412,"start":4538,"enrollment":4539,"conditions":4540,"interventions":4541},"NCT01454752","Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition",[92],"2011-11",860,[15,18],[4520],{"intervention":4543,"totalTrials":129,"cells":4544},"amodiaquine-artesunate (AQAS) fixed-dose",{"EARLY_PHASE1":4545,"PHASE1":4547,"PHASE2":4549,"PHASE3":4551,"PHASE4":4553,"NA":4555},{"trials":4546,"activeCount":99},[],{"trials":4548,"activeCount":99},[],{"trials":4550,"activeCount":99},[],{"trials":4552,"activeCount":99},[],{"trials":4554,"activeCount":99},[],{"trials":4556,"activeCount":99},[4557],{"nctId":4558,"briefTitle":4559,"status":111,"phases":4560,"primaryCompletion":4561,"completion":4562,"start":4563,"enrollment":4564,"conditions":4565,"interventions":4566},"NCT01967472","Adherence to Antimalarial Drugs in Sierra Leone",[92],"2013-12","2014-01","2013-09-16",1145,[15],[4543,4567],"Artemether-lumefantrine combination (AL) dispersable",{"intervention":4567,"totalTrials":129,"cells":4569},{"EARLY_PHASE1":4570,"PHASE1":4572,"PHASE2":4574,"PHASE3":4576,"PHASE4":4578,"NA":4580},{"trials":4571,"activeCount":99},[],{"trials":4573,"activeCount":99},[],{"trials":4575,"activeCount":99},[],{"trials":4577,"activeCount":99},[],{"trials":4579,"activeCount":99},[],{"trials":4581,"activeCount":99},[4582],{"nctId":4558,"briefTitle":4559,"status":111,"phases":4583,"primaryCompletion":4561,"completion":4562,"start":4563,"enrollment":4564,"conditions":4584,"interventions":4585},[92],[15],[4543,4567]]